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Abstract: 
While the genes involved in most forms of sporadic or recessive ataxia with 
mental retardation are still unknown, exome sequencing is a promising tool to 
identify novel genes in rare disorders. Previously, two siblings in a 
consanguineous Turkish family were reported, who presented with a non-
progressive ataxia syndrome including congenital truncal and extremity ataxia, 
cerebellar hypoplasia, hypotonia, developmental delay, mental retardation and 
nystagmus.  After exome sequencing and filtering by homozygosity, we identified 
a homozygous mutation at the invariant +1 position (c. 964+1 G>A) in intron 9 of 
the CWF19L1 (complexed with cdc5 protein 19-like 1) gene.  This mutation is 
absent in >6,500 European and African American individuals and 200 Turkish 
control DNAs. In lymphoblastoid cell lines from affected individuals, the mutation 
causes exon skipping, reduction in mRNA levels, and protein loss. Morpholino-
mediated knockdown in a zebrafish model demonstrates that loss of the 
evolutionarily highly conserved CWF19L1, whose normal biological function is 
unknown, alters cerebellar morphology and causes movement abnormalities. 
Preliminary data suggests this protein is expressed in a tissue-specific manner 
and that this protein is localized in the nucleus. Our results suggest that we have 
identified a novel cause of recessive ataxia and developmental delay.  !
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Chapter I. 
Introduction 
 
Ataxia is a disorder of the cerebellum characterized by lack of coordinated, 
voluntary movements. Acquired ataxias are caused by insult to the cerebellum, 
either by acute alcohol or toxic incidence, blunt force trauma to the head, or as a 
secondary symptom in other disorders including paraneoplastic diseases and 
multiple system atrophy 1,2. While ataxia can be acquired, many ataxia disorders 
have an underlying genetic cause. 
 
Hereditary ataxias are a clinically and genetically heterogeneous group of 
disorders. To date, greater than 50 genes have been implicated in ataxia, with 
these genes involved in many molecular mechanisms in the cell3,4. Many 
inherited ataxias are caused by gain- or loss-of-function mutations in genes, 
however the genetic etiology is unexplained in ~40% of cases5,6. Hereditary 
ataxias have several modes of inheritance including dominant, recessive, x-
linked, and mitochondrial but the majority of the ataxia disorders are of dominant 
or recessive inheritance2,5,7.  
 
Dominant ataxias  
! 2!
 
Autosomal dominant cerebellar ataxias (ADCAs) consist of the spinocerebellar 
ataxias (SCA), which are generally caused by repeat expansions, and episodic 
ataxias (EAs) generally caused by defects in ion channels. ADCAs often have a 
later age of onset, over 40 years of age, and are often progressive, with 
worsening ataxia symptoms and cerebellar atrophy, significantly impacting the 
quality of life of the affected individuals1,2,5,8. Anticipation is a common 
phenomenon in the repeat expansion disorders where severity of the disease 
increases, due to expansion of the repeat, in succeeding generations1,2,8–10. 
Along with ataxic gait and cerebellar deficits, ophthalmological abnormalities and 
non-neurological signs and symptoms can accompany dominant ataxias. With 
the advent of advanced sequencing technologies, recent studies provide 
evidence for conventional (frameshift, missense, and nonsense) mutations in 
dominant ataxia11. Although the genetic etiology is defined for many of the 
dominant ataxias, it is estimated that many patients have rare mutations that are 
currently undefined5. 
 
Recessive ataxias 
Autosomal recessive cerebellar ataxias (ARCAs) are recessively inherited 
neurological disorders that are characterized by incoordination, delayed motor 
development milestones, and early age of onset, before 25 years of age1,8–10. 
While most forms of ataxia are individually rare, recessive ataxias are 
cumulatively not uncommon, with an estimated frequency of 1/20,000 that varies 
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between countries5,7. ARCAs are genetically heterogeneous and are clinically 
classified in four different groups based on genetic etiology and common 
phenotypes: congenital ataxias, usually defined by abnormal development of the 
cerebellum or brainstem; metabolic ataxias, marked by metabolic disorder and 
where ataxia may be a minor symptom; DNA repair defect ataxias, marked by 
mutations in genes that are involved in DNA repair; and degenerative and 
progressive ataxias, due to mutations in mitochondrial genes and severe 
progression of the disorder9,12.  
 
Currently 21 ataxia genes are routinely tested in the clinic in cases of suspected 
recessive inheritance. In many of these cases, however, results are negative, 
suggesting that several recessive ataxia genes are still unknown5. Identifying 
additional recessive ataxia genes may lead to improved clinical testing, which 
would help in diagnosis. Establishment of a genetic cause can help provide 
prognostic information to the family. Additionally, gene identification may reveal a 
molecular mechanism or pathway that is currently unknown to play a role in 
ataxia or cerebellar function. Alternatively, the gene may play a role in an already 
known ataxia pathway, in which case knowledge of that ataxia pathway or 
network will be expanded13,14. As ataxias are genetically heterogeneous and 
some rare ataxias are caused by private mutations existing only in that particular 
family, development of ataxia pathways will be essential to provide larger scale 
targets for therapies.  
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Rare recessive ataxia in a consanguineous Turkish family 
Two Turkish families were identified by Yapici and Eraksoy (families 1 and 3), 
family 3 is consanguineous15. Two pairs of siblings were affected with a non-
progressive, congenital ataxia in an autosomal recessive inheritance pattern. 
Symptoms include hypotonia, developmental delay, mental retardation, 
nystagmus, truncal and extremity ataxia and cerebellar hypoplasia. Blood was 
collected from the affected children in the two families and mailed to the 
Burmeister lab for DNA extraction. Because the same physician referred both 
families from Turkey, we hypothesized that a founder mutation of common origin 
was the cause of the ataxia. Linkage analysis was performed on the 4 children of 
2 families, and several regions of interest were identified. Several candidate 
genes were identified by linkage analysis, including KCNK1 and GLRX2, 
however no variants were found. High density genotyping demonstrated no 
overlapping linkage and homozygosity regions, suggesting a founder mutation is 
unlikely. Therefore, we focused on identifying the mutation in the 
consanguineous family as consanguinity adds power to linkage analysis in small 
families16. The parents and a third sibling were clinically healthy. Negative testing 
for ataxia genes suggested a mutation in a novel gene or mutation in a gene that 
is not currently included in a clinical panel. 
 
Gene identification methods 
There are multiple methods to identify genetic etiologies for disorders17–19. Two 
traditional methods include functional cloning and positional cloning. In functional 
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cloning, the position of the gene is not necessary; genes are chosen based on 
the biological defect in the disorder17 . This method has been used successfully 
to clone the genes for phenylketonuria (PAH) and sickle cell anemia (HBB)17. 
This method is most useful for disorders that have a biochemical defect and are 
homogeneous in their causes. Positional cloning is another method that is useful 
for identifying genetic candidates. Positional cloning does not assume any 
particular function of the candidate genes; it is based only on map location. A 
major step in positional cloning is linkage analysis. Linkage analysis uses a panel 
of genome-wide polymorphic markers to identify regions where the disease locus 
is located. It is based on the premise that markers nearest the mutation will 
segregate through generations with the mutation, as the probability of 
recombination between those regions is reduced, demonstrating proximity, or 
linkage, to the mutation. Linkage analysis maps regions where candidate genes 
may be located. These regions are then searched for potential candidate genes 
based on their function or involvement in similar disorders. These candidates can 
then be sequenced by the Sanger method to identify variants17. Positional 
cloning has proven to be effective for cloning the genes in multiple genetic 
disorders including Duchenne muscular dystrophy, Bardet-Biedl syndrome, and 
SCA120–22. 
 
Homozygosity mapping is a special form of linkage analysis generally applied to 
families of consanguineous marriage, although it can be used for outbred 
individuals as well18,16,23 . This method is used for identifying loci that remain 
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homozygous over several generations. Homozygosity mapping tests the 
assumption that the causative mutation is “identical by descent”, or that the 
affected individual (or individuals) received one copy of the mutated allele from 
each parent. Mutations of interest are likely to exist in large spans of 
homozygous loci due to decreased opportunity for recombination between these 
loci and the disease causing mutation. These homozygous regions can then be 
mapped and used to identify candidate genes in order to screen for 
mutations16,24.  
Next generation sequencing has recently become a more popular method for 
identifying novel variants. Next generation sequencing allows for rapid 
sequencing of either the whole genome or the coding genome (exome) of a 
patient. Exome sequencing has proven to be an effective method to identify 
novel variants because 85% of all known disease causing mutations are found 
within coding or nearby regulatory regions (5’UTR, 3’UTR, splice sites)25. Exome 
sequencing is also cost effective at less than $1000 per sample 5,25.  
 
These methods have proven to be useful in identifying disease-causing variants; 
however, they have their limitations. The functional cloning approach is 
implausible in heterogeneous disorders, as our knowledge is too limited to 
identify genes based on function. This method would prohibit gene discovery for 
genes that encode proteins in which the function is unknown or has multiple 
functions. Rare genetic disorders are often studied in single, sporadic, individuals 
or individual families providing another barrier to gene identification. These 
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families are not large enough to perform informative linkage analysis or the 
mutations are private. In these cases, positional cloning and homozygosity 
mapping are expensive and laborious methods as they can provide a 
cumbersome number of candidates and difficulty increases with heterogeneity of 
the disorder. Exome sequencing also identifies a large number of potential 
causal variants; therefore, in rare or heterogeneous disorders it is often 
necessary to combine exome sequencing with linkage or homozygosity regions 
to reduce the candidate list and identify the variant26–28. Furthermore, exome 
sequencing may exclude variants by filtration methods such as non-coding 
variants, lack of functional association, or extent of allele frequency in non-ataxic 
populations.  
 
The above methods are useful for identifying gene variants; however, damaging 
variants exist in personal genomes29,30, therefore independent lines of evidence 
are necessary to show that a variant is causal. Ideally, rare, novel variants are 
found in additional individuals with the same disorder, demonstrating that the 
mutation causes the disorder. However, it is often the case that rare mutations 
are unique to a family, requiring verification by independent methods. 
 
Animal models of ataxia 
Development of animal models can demonstrate the impact of a mutation at the 
organismal level and can be used to discover the molecular mechanisms by 
which a gene causes a disorder. Animal models are advantageous research 
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tools in neuro-genetic disorders because they provide a source of tissue to study 
the effects of the mutation at the cellular and molecular levels, as human brain 
samples are usually unavailable to researchers. These animal models can then 
be used to test potential therapies31–35.  
 
Animal models have been particularly useful in identifying or validating genes 
involved in ataxia disorders36. Naturally occurring mouse models, such as 
Nagoya which has a mutation in Cacna1, have provided essential information 
about the function and physiology of their affected genes and mutations in many 
of these genes have been implicated in human ataxias as well36,37. Knockout and 
conditional mouse and Drosophila models are also generated to study the impact 
of ataxia mutations. Multiple models for the same or similar disorders prove 
advantageous when differences in genetic mutations, phenotypes, and 
physiology cannot be effectively studied in a particular model due to embryonic 
lethality or differential development36. For example, in SCA7, loss of the 
Drosophila ataxin-7 protein caused neural and retinal degeneration and early 
lethaiity38. Additionally, severe knockdown of zebrafish ataxin-7 led to deformed 
embryos and early lethality, however, moderate knockdown of ataxin-7 
demonstrated the requirements of ataxin-7 in neuronal and retinal development 
allowing39.  
 
Another recent ataxia animal model is the zebrafish40. As zebrafish share basic 
vertebrate brain structure, they have been used to study human neuro-genetic 
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disorders, including ataxia, Parkinson’s disease and bipolar disorder40–43. 
Zebrafish are advantageous research animals because of their rapid generation 
time, large numbers of offspring, quantifiable behavior, ex-utero development, 
and transparency of developing embryos40,42,43. Zebrafish have been utilized to 
validate mutations44,45, demonstrated conserved function46,47, and investigate 
molecular mechanisms of genes implicated in ataxia48,49,39. Expression of mutant 
dominant negative RNF170 in zebrafish has been used to show disrupted 
embryonic development44. Knockdown of rnf216 and otud4, discovered to cause 
ataxia with hypogonadism in a digenic manner, demonstrate abnormal 
development of the optic tectum and cerebellum of the fish, validating 
pathogenicity of the mutations45.  These studies, suggest zebrafish are a feasible 
model to use to analyze the behavioral and developmental impact of ataxia 
mutations. 
 
The zebrafish cerebellum has organizational similarities to the human cerebellum 
as it has a molecular layer, Purkinje cell layer, and granule cell layer50,51. The 
cells contained in these regions are similar to humans as the Purkinje cell layer 
contains inhibitory neurons that use gamma-aminobutyric acid (GABA) and/or 
glycine as their major neurotransmitter and the granule cell layer consists of 
excitatory neurons that use glutamate as a primary neurotransmitter50. The 
zebrafish cerebellum is, however, different in some ways from the human 
cerebellum. The zebrafish cerebellum is composed of three parts, two of which 
have the three-layer structure and one that only contains granule cells. 
! 10!
Additionally, the zebrafish cerebellum contains eurydendroid cells, which are 
thought to be similar to the deep cerebellar nuclei (DCN) that are the major 
output tract from the human cerebellum, but the molecular machinery of the 
eurydendroid cells is not well described50. Additionally, the zebrafish brain has 
cerebellum-like structures outside of the cerebellum that contain granule cells, 
but the function of these structures is unknown50. 
 
While the zebrafish brain has some differences from the human brain, models of 
genes implicated in ataxias have demonstrated changes in brain, particularly in 
the cerebellum, suggesting some conservation of the function of these genes and 
the importance of these genes in the cerebellum. Knockdown of Ataxin-7, the 
mutated gene in SCA7, showed defects in development of photoreceptors and 
Purkinje and granule cells of the cerebellum39. Knockdown of the zebrafish CA8 
gene demonstrated a decrease in cerebellar size, increase in neuronal apoptosis 
and increase in abnormal motor movements similar to the phenotype seen in 
patients47. 
  
Additionally, behavioral analysis has been used to demonstrate the impact of 
ataxia gene mutations in zebrafish models47,48. Early movement in fish is largely 
attributed to spinal cord neurons. However, lesions of the hindbrain, where the 
cerebellum is located, has been shown to affect swimming ability in larval 
zebrafish suggesting the hindbrain is important in larval movement52. 
Pathogenesis of the potassium (Kv3.3) channel mutation in SCA13 was 
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demonstrated by expression of mutant Kv3.3 in zebrafish. This model revealed 
changes in the excitability of motor neurons and changes in motor response to 
startle48. A zebrafish model of the epilepsy, ataxia, sensorineural deafness, and 
tubulopathy (EAST) syndrome shows that knockdown of kcnj10 in fish 
demonstrates abnormal motor behavior and kidney dysfunction41. This model of 
EAST in the zebrafish is also advantageous to study the brain regions affected 
by kcnj10 knockdown as knockout mice demonstrate abnormal brain morphology 
and are embryonic lethal53. Taken together, these studies indicate the zebrafish 
is a feasible model to analyze the impact of ataxia mutations.  
 
Summary  
Although greater than 50 genes have been implicated in ataxia, it is estimated 
that 40% still have an unexplained genetic etiology5. Many of the unexplained 
ataxias occur sporadically or in families that are not amenable to use of 
traditional methods, indicating the necessity for new methods to identify genetic 
causes. Recently, exome sequencing has been used to identify genes involved in 
rare neurological disorders, including ataxia5,54–57.  Positive results are often 
obtained in families with consanguinity5, as homozygosity further narrows down 
the linkage evidence16, and homozygous mutations are easier to detect than two 
compound heterozygotes58. Discovery of these additional ataxia genes will help 
to increase our understanding of the pathophysiology of this disorder, establish 
methods to test gene function and may lead to targets for therapeutic treatment.  
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The goal of this dissertation was to identify the gene involved in a rare ataxia 
disorder using a combination of homozygosity mapping and exome sequencing 
in a small consanguineous family. As the mutation was in a gene not previously 
demonstrated to play a role in ataxia, we utilized molecular methods to 
demonstrate the impact of the mutation on expression of the gene, characterized 
normal expression of the protein in cells and tissues, and established a zebrafish 
animal model to demonstrate functional importance of the gene in an organism.  
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Chapter II. 
 
Exome sequencing identifies a splice mutation in CWF19L1 in a 
consanguineous recessive ataxia family  
 
Introduction 
Autosomal recessive cerebellar ataxias are a clinically and genetically 
heterogeneous group of neurological disorders characterized by deficiencies in 
the coordination of movements, most prominently the limbs, trunk and eyes. 
While most forms of ataxia are individually rare, recessive ataxias are 
cumulatively not uncommon, with an estimated frequency of 1/20,000 that varies 
between countries 5,7. Most suspected recessive ataxia cases test negative for 
the 21 ataxia genes that are routinely included in clinical genetic testing 5, 
suggesting that many recessive ataxia genes are still unknown. Many families 
that present in the clinic with ataxia of unknown origin are too small to allow gene 
identification by traditional genetic methods, such as positional cloning. 
Additionally, the genetic heterogeneity of the ataxia disorders presents a time 
consuming and costly barrier in the laboratory for identifying gene candidates in 
small families.  
 
In 2005, a small consanguineous (parents are first cousins) Turkish family was
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described in which two siblings were affected with a non-progressive, congenital 
ataxia in an autosomal recessive inheritance pattern. Symptoms include 
hypotonia, developmental delay, mental retardation, and truncal and extremity 
ataxia. The patients were negative for clinical tests for other organ system 
involvement, including skeletal X-rays, optic atrophy, and metabolic tests 
commonly administered to individuals with unexplained ataxia. MRI 
demonstrated vermian hypoplasia in association with hypoplasia of the cerebellar 
hemispheres15. The parents and a third sibling were clinically healthy.  
 
Recently, next generation sequencing has proven to be a time- and cost-effective 
method when identifying novel gene candidates especially when used in 
combination with other genetic approaches, such as gene expression analysis 
and homozygosity mapping23,58. Next generation sequencing has recently been 
used to identify genes involved in rare neurological disorders 5,59, including 
ataxia6,60–63, which has been helpful in annotating gene pathways and creating 
new targets for therapeutic intervention. Thus we set out to identify a novel 
genetic cause for this rare form of recessive ataxia in this family by combining 
next generation sequencing, linkage analysis and expression analysis.  We also 
investigated the impact of the novel variant on mRNA stability and protein 
expression. 
 
Materials and Methods 
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Human Subjects 
Informed consent was obtained from participants and the Institutional Review 
Board of the University of Michigan Medical School approved this study. 
Heparinized blood from the affected individuals was separated by density 
centrifugation and transformed with Epstein Barr virus (EBV)64 to create patient-
specific lymphoblastoid cell lines. After growth initiation, aliquots of the cells were 
frozen and grown as needed.  
 
Homozygosity mapping and exome sequencing 
Homozygosity mapping was performed by hybridizing DNA from both affected 
individuals to high-density Sentrix Human Hap 550 genotyping chips (Illumina). 
Linkage analysis was performed by hybridizing DNA from both affected 
individuals to Infinium HumanLinkage-12 genotyping chips (Illumina) and data 
analyzed using Merlyn. Note: these linkage chips are no longer being sold.  
Exome capture was performed with the NimbleGen SeqCap EZ Exome Library 
v1.0 kit (Roche, Indianapolis, IN). The exon-enriched DNA from both affected 
individuals was sequenced with an Illumina HiSeq2000 instrument at the 
University of Michigan DNA Sequencing Core to an average depth of coverage of 
20x. The exome data was filtered to variants that were 1) in the homozygosity 
regions, 2) homozygous in both individuals, and 3) predicted to change the 
protein sequence or expression (missense, nonsense, splice variants). 
 
PCR and Sequencing 
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DNA was extracted from EDTA (lavender) blood samples using the Puregene 
Blood Core Kit (Qiagen). RNA was extracted from lymphoblastoid cell lines using 
TRIzol reagent according to the manufacturer’s (Life Technologies, Grand Island, 
NY) instructions. RNA was subjected to DNase I treatment (Ambion, Grand 
Island, NY) and reverse transcribed using the Invitrogen (now Life Technologies, 
Grand island, NY) SuperScript II reverse transcription kit using Oligo dTs and 
random hexamers.  
 
Sequence data were compared with the CWF19L1 reference sequence 
NC_000010.11 (DNA) or NM_018294 (mRNA) with Lasergene software 
(DNAStar, Madison, WI). 
 
CWF19L1 splice variant was also screened in 203 DNA samples (406 
chromosomes) from controls consisting of the parents and unaffected sibling and 
200 unaffected Turkish individuals. Additionally, 64 DNA samples (128 
chromosomes) of unrelated ataxia patients were screened for other CWF19L1 
variants by Sanger sequencing. 
 
Primers for sequencing the novel CWF19L1 variant spanned exon 9 and the 
flanking intronic regions (F: 5’-CAG GAA GAA TCA GCC TGT CAG TT-3’; R: 5’-
GGC CAA GGC CAT GTT TAT ATT T-3’). RT-PCR included primers that 
spanned exons 8 to 10 (F: 5’-GCC TCC GGA TGT CAC TGA AAA CCC T-3’; R: 
5’-GGG CTA GCA AGG CAA AAC CAG CA-3’), exon 9 (F: 5’-GCC CCT GTG 
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GAA GAA TCA GCC TGT C-3’; R: 5’-GCA GGG TCC TGG AGG CTG AGG AG-
3’), exons 7 to11 (F: 5’-TGC ACA GCA TGC CAC CCG GTT T-3’; R: 5’-TCC TTT 
GGC CAG GGC AAG GTA GC-3’) and exons 10 to14 (F: 5’- ACC CTG CTG 
GTT TTG CCT TGC T-3’; R: 5’- GGG CTC AAA GTC TTT CCG GAA GCG G-3’).  
 
Microarray and qRT-PCR 
RNA was extracted from lymphoblastoid cell lines (LCLs) of the affected siblings 
and from 28 cell lines from controls or individuals affected by other conditions. 
cRNAs was prepared by standard methods and hybridized to Illumina human 
genome expression micro-array (RefSeq8). Data was analyzed using Illumina 
BeadStudio.  
 
qRT-PCR was performed on iQ5 cycler (BioRad, Hercules, CA). Assays were 
performed in 20 µl reaction mixtures, using a SYBR Green Master Kit, following 
the manufacturer's protocol. All measurements were done in triplicate. The 
threshold cycle value for each product was determined and normalized to that of 
the internal controls, GAPDH and β-actin. qRT-PCR results were analyzed using 
MyQ (BioRad, Hercules, CA). 
 
Primers amplified sequence that spanned exon 6 (F: 5’-TTG GGA ATT CTT CTG 
GAG AAG TGG A-3’; R: 5’-GGT CTT TTC CAA AGC AGC AAA ATG G-3’), 
exons 8-10 (F: 5’-GCC TCC GGA TGT CAC TGA AAA CCC T-3’; R: 5’GGG CTA 
GCA AGG CAA AAC CAG CA-3’), and exon 11(F: 5’-GCC CTG GCC AAA GGA 
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GGC TT-3’; R: 5’-CTG TAG CTG GAG GTG ATG GCT CTT-3’). The reference 
gene primers amplified GAPDH (F: 5’-GAG TCA ACG GAT TTG GTC GT-3’; R: 
5’-AAT GAA GGG GTC ATT GAT GG-3’) and RNA POL II (RPII) (F: 5’-CTC TTC 
CAG CCT TCC TTC CT-3’; R: 5’-AGC ACT GTG TTG GCG TAC AG-3’).  
 
Protein electrophoresis and immunoblotting 
Three batches of LCLs, each consisting of two homozygotes and two controls 
were cultured for 2 to 3 weeks, and lysate was prepared in RIPA buffer 
containing HALT protease inhibitor mixture (Thermo Scientific). Equal amounts of 
protein (30 µg per experiment) were electrophoresed on SDS-PAGE gels. SDS-
PAGE gels were prepared to 10% polyacrylamide and were large gels 
(separating gel volume of 25ml volume, ~10 inches in length, 1mm thick). 
Samples were mixed with 2X Laemmli buffer with β-mercaptoethanol and heated 
at 100oC for 5 minutes. Gels were run in 1X Tris-Glycine-SDS running buffer at a 
constant current of 15-30 milliamps and electrophoretically transferred at a 
constant current of 100 milliamps overnight at room temperature in 0.5X Tris-
Glycine buffer onto a nitrocellulose membrane (Pall Life Sciences, BioTraceTM 
NT, Cat. No. 66485). Ponceau S staining of nitrocellulose membranes was 
performed according to the manufacturer’s protocol (USB, Cat. No. 32819, 
prepared as directed) to confirm transfer of proteins onto the membrane. 
 Membranes were incubated in blocking buffer (5% wt/vol non-fat dry milk 
powder in TBST) for at least 1 hour. Primary and secondary antibodies were 
diluted in blocking buffer and subsequently incubated with intermediate washes 
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for 1 hour at room temperature. For C19L1, we used primary antibody 
HPA036889 (Sigma, St. Louis, MO) at a dilution of 1:2000; the secondary 
antibody was HRP-conjugated antibody against rabbit IgG diluted 1:10,000 
(BioRad, Hercules, CA, Cat. No. 170-6515). All washes were performed 3 times, 
10 minutes each, in TBST. Reactions were visualized using BioRad Clarity 
Western ECL substrate (BioRad, Hercules, CA, Cat. No. 170-5061). Blots were 
stripped with Restore Western Blot Stripping Buffer (Thermo Scientific Cat No. 
21059) and reprobed with primary antibody β-Tubulin (Abcam, Cambridge, MA) 
at a dilution of 1:1,000 using the same secondary antibody and ECL Western 
Blotting Substrate (BioRad, Hercules, CA). 
In silico analysis 
H. sapiens (C19L1): NP_060764.3 
S. pombe (mug161): NP_593012.1 
H. sapiens (C19L2): NP_689647.2 
S. pombe (cwf19): NP_593208.1 
BioGPS65, PomBase66  and UniProt67  were used to identify all cwf genes, 
subcellular localization and function.  
 
Results 
Exome sequencing identifies a mutation in CWF19L1 in affected siblings 
The consanguineous family (parents are first cousins) has been previously 
described15. Two siblings, but not their parents or their unaffected sibling, are 
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affected with hypotonia, developmental delay, mental retardation, and non-
progressive truncal and extremity ataxia. MRI demonstrated vermian hypoplasia 
in association with hypoplasia of the cerebellar hemispheres15 (Figure 2.1). To 
identify candidate genes causing ataxia in this family, we used whole-exome 
sequencing filtered by homozygosity. Homozygosity mapping identified 13 
regions > 500kb, spanning a total of 71 Mb, ~2% of the genome, as homozygous 
and shared between the siblings, reaching LOD scores of 1.0-1.8 (Figure 2.1). 
These regions contained 485 candidate genes, but no previously known ataxia 
genes.  
 
Exome sequence variants were filtered for (a) being on target (in or near exons), 
(b) the homozygosity regions, and (c) predicted damaging function (nonsense, 
missense and splice variants, see Figure 2.2). 4,969 of the exome variants were 
shared between the siblings, and of these shared variants 713 were 
homozygous. 28 of the shared and homozygous variants mapped to 
homozygosity regions, with onl 17 of those within coding regions (Table 2.1). 
Three variants were potentially damaging: 2 missense mutations in conserved 
amino acids and one splice site mutation (Table 2.1). We tested all 17 variants 
using Sequenom’s MassARRAY genotyping analysis in the patients and 202 
unrelated individuals. None of the three most promising variants were present in 
202 American controls, but several of the 14 others could be excluded because 
they were present in controls. The 3 promising variants were also absent from 
the 13,000 chromosomes available in the EVS server (National Heart, Lung, and 
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Blood Institute Exome Variant Server (NHLBI GO Exome Sequencing Project 
ESP), Seattle, WA (URL:http://evs.gs.washington.edu/EVS/) [October 2011, 
similar results February 2014]).  
 
Of the three candidate gene mutations, two were unlikely to cause ataxia: a 
missense mutation in CDC73, since other mutations in this gene cause 
hyperparathyroidism, jaw syndromes and cancer68,69, and a missense mutation in 
GSTO1, since mutations in GSTO1 in humans and loss of GSTO1 in mice and 
drosophila do not cause any discernible phenotype 70–72. The third candidate 
mutation was a mutation in CWF19L1 in an obligatory splice site (c. 964+1 G>A, 
i.e. the first base of intron 9, always G, is changed to an A, Figure 2.3). Use of 
bioinformatic sites such as HPRD10, Ensembl11, and FANS12 identified the G>A 
variant in CWF19L1 as a change in an obligatory splice site that is predicted to 
be highly damaging to the protein. While the function of the CWF19L1 gene is 
unknown, it is highly conserved across species, suggesting the evolutionary 
importance of this gene. Taken together, CWF19L1 was the most promising 
candidate gene variant (Figure 2.2).  
 
Sanger sequencing confirmed the CWF19L1 mutation in the affected siblings and 
demonstrated that it is absent in 200 Turkish individuals without neurological 
disorder. The parents are each heterozygous for this mutation and the unaffected 
sibling is homozygous for the reference allele (Figure 2.3). In 64 other subjects 
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with ataxia, we detected none who were homozygous or compound 
heterozygous for damaging CWF19L1 mutations. 
 
Splice mutation causes exon skipping, decreased mRNA levels, and loss of 
protein 
The splice donor site mutation after exon 9 is predicted to eliminate a splice site 
immediately following exon 9. We tested this prediction by analyzing mRNA from 
lymphoblastoid cell lines (LCLs) of the two affected siblings and control cell lines. 
RT-PCR for the segment spanning exons 8-10 revealed a product of 234bp in 
control individuals. However, RT-PCR of RNA from both affected individuals 
demonstrated a smaller product of 119 bp. Sanger sequence analysis of the RT-
PCR products showed a short cDNA splice product missing 119 bp that are 
equivalent to all of exon 9 (Figure 2.4). In order to determine the full impact of the 
mutation on mRNA processing, we performed RT-PCR using primers specific to 
exon 9 and other exons of CWF19L1 and found no evidence of any exon 9 
transcript in the affected individuals and no additional splicing aberrations (Figure 
2.5). 
 
As the cellular machinery reads the bases of mRNA transcripts in sets of 3 for 
protein translation, deletion of the 119 bases of exon 9, which is not divisible by 
three, causes a shift in the reading frame of this mRNA. This frameshift is 
predicted to cause a different translation from the canonical protein and is 
predicted to cause translation of an early “STOP” codon 60 amino acids 
! 28!
downstream of exon 9. The truncation of this aberrant protein is predicted to 
cause mRNA transcripts to undergo nonsense-mediated decay, which would 
cause decreased levels of CWF19L1 mRNA in affected individuals. To test if the 
mutation affects gene expression, we extracted RNA from lymphoblastoid cell 
lines (LCLs) from the affected siblings and 28 other individuals, prepared cRNAs, 
and hybridized them to Illumina human genome expression micro-arrays 
(RefSeq8). The level of expression of CWF19L1 in (LCLs) from the two affected 
children was 2 to 8-fold less when compared to 28 other individuals (ranked 
within the 10 largest expression changes for these two affected individuals) 
(Figure 2.6) while expression of GSTO1 and CDC73 were unchanged. However, 
because our sample size is only 2, a formal analysis of whether the difference is 
significant was not possible. Since the other samples are not from children, and 
not from Turkey, this result by itself is not convincing, but is an additional piece of 
evidence to consider in the overall assessment of a candidate gene. To further 
quantify the expression changes, we performed qRT-PCR using primers 
designed to CWF19L1. Normalized against GAPDH and ACTIN-β mRNA from 
the affecteds is ~6-fold reduced compared to that of control (n=3) individuals 
(Figure 2.7).  
 
The CWF19L1 gene is predicted to produce 3 different protein isoforms from 
different methionine start sites (in exon 1, in exon 5 and in exon 9)67. The 
CWF19L1 variant was shown to cause skipping of exon 9 and decreased levels 
of CWF19L1 mRNA, potentially causing a significant decrease or ablation of 
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C19L1, the protein encoded by CWF19L1.  Since exon 9 is included in all 
isoforms, the CWF19L1 variant would be predicted to impact all protein isoforms 
(Figure 2.8A). In order to test the hypothesis that protein is affected by the 
CWF19L1 splice site mutation, we performed Western blots using proteins 
extracted from LCLs of the affected siblings and control individuals. Immunoblot 
was performed using commercial antisera for C19l1 (Sigma) and β-Tubulin. The 
C19L1 antisera recognizes an epitope 5’ to the mutation, causing it to detect two 
of the three isoforms (Figure  2.8A). Western blot analysis demonstrated that 
control individuals (lanes 1 and 3, Figure 2.8B) have a two-band pattern for 
C19L1 while the patients (lanes 2 and 4, Figure 2.8B) show no bands for C19L1. 
The absence of protein bands in the patients demonstrates specificity of this 
antiserum. In affected individuals, there was no evidence for presence of normal 
or the predicted truncated (344 amino acid; mw 38kDa) protein, even when 
overloading or overexposing the blot suggesting true loss of the protein in the 
affected siblings. !
Discussion  
Using a combination of homozygosity mapping and next generation sequencing, 
we have identified a novel genetic candidate for a rare, recessive ataxia-mental 
retardation syndrome. Many recent studies have demonstrated the use of 
homozygosity mapping and exome sequencing in the identification of candidate 
genes in small families and even in single individuals. These studies include 
genetically heterogeneous disorders such as ataxia63,73–75. It is estimated that 
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40% of recessive ataxias still have unknown etiology 5; therefore, discovery of 
this gene identifies a novel cause for ataxia which may lead to the identification 
of novel pathways in ataxia or may uncover a role for this gene in current ataxia 
pathways.  
 
While CWF19L1 is a good candidate gene, all other damaging variants in the 
exome should be evaluated for their pathogenicity as to not exclude de novo 
variations in this family. Analysis of other homozygous variants that were in genic 
regions and were predicted to change the encoded protein (missense, nonsense, 
splice changes; Table 2.2) identified no variants or genes that were previously 
associated with ataxia or neurological disorders. Also, none of these genes 
turned out to be potential causal genes based on their function or brain 
expression. Interestingly, most of the homozygous exome variants were intronic, 
non-damaging, or in noncoding regions (5’ UTR and 3’UTR). Therefore, the 
genetic and molecular data that demonstrate linkage and homozygosity at the 
locus and damaging impact of the mutation on the expression of the gene 
provide convincing  evidence that CWF19L1 is the causal gene.  
 
The identification of a mutation in CWF19L1 in siblings with congenital ataxia 
suggests that this gene plays a role in neuronal development. We postulate that 
the C19L1 protein is important in the normal development of the brain, and 
especially the cerebellum, since the affected individuals are affected with 
cerebellar hypoplasia15. This suggests that severe deficiency or loss of the 
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protein causes abnormal development. CWF19L1 encodes three protein 
isoforms. Our data suggest that the mutation leads to a null allele, as RT-PCR 
detected no evidence of mRNA that included exon 9 in affected individuals and 
no protein could be detected even by overexposure (not shown). We also did not 
detect the truncated protein product, which translates 60 aberrant amino acids 
after the end of exon 8 before the “STOP” codon, suggesting rapid degradation 
of this aberrant protein. Our data, however, does not differentiate between a 
severe hypomorph and a null allele, since we can’t exclude the possibility that 
some normal splicing persists, and a small amount of normal protein is made 
below our level of detection.  
 
The function of the CWF19L1 encoded C19L1 protein is unknown. CWF19L1 is 
the gene symbol for “complexed with cdc5 protein-like 1” after the cwf19 gene in 
S. pombe. There are 29 genes annotated in Pombase, an online resource for 
fission yeast, as  “complexed with cdc5 protein” . Many of these cwf proteins 
have human orthologs (Table 2.3) 66,67,76. These 29 cwf genes were identified in 
a large-scale proteomics assay that utilized tandem affinity purification and mass 
spectrometry to identify the components of the fission and budding yeast multi-
protein splicing complexes77,78. While the cwf19 protein was found in the 
spliceosome in yeast and humans77,79, it is unclear whether it has an essential 
role in the spliceosome or if it performs an accessory role77–79. Some of the other 
cwf proteins have been shown to play an accessory role in the spliceosome, but 
also perform other functions in the cell, suggesting multiple actions of those cwf 
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proteins (Table 2.3, column 8)67,80. CWF19L1 may play additional roles in the 
cell, as CWF19L1 has been shown in a large human yeast two-hybrid study to 
interact with TOM1L1, a Src-activating and signaling molecule, which is not 
present in yeast.  
 
While human CWF19L1 is named for cwf19, the orthologous S. pombe gene is 
mug161 (meiosis up-regulated 161)66,67. Human CWF19L1 is part of the CWF19 
protein family, proteins that contain two C-terminal CwfJ domains (Figure 4.9). 
Interestingly, the orthologs to mug161 also have an N-terminal 
metallophosphatase (MPP) domain (Figure 2.9) suggesting they have different or 
additional function when compared with the cwf19 orthologs66,67,76.   
 
The CwfJ domain is particular to the cwf19 family of genes and is not described 
in the literature. Within the first CwfJ domain, C19L1 is predicted to have a 
Histidine Triad (HIT)-like domain66,67,76. Proteins with HIT- domains belong to a 
superfamily of nucleotide hydrolases and transferases that act on 
ribonucleotides81. These proteins are traditionally classified into three branches: 
Histidine Triad Nucleotide Binding (HINT), which are adenosine 5’-
monophosphoramide hydrolases that have tumor suppressor properties; Fragile 
histidine triad (FHIT), which are diadenosine polyphosphate hydrolases and also 
have tumor suppressor properties, and finally the Galactose-1-phospahate 
uridylyltransferase (GalT) branch, which consist of specific nucleoside 
monophosphate transferases81–83. While the HIT domain containing proteins 
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have been linked with tumor suppression, mutations in these proteins have also 
been shown to cause axonal neuropathy84,85. Although these HIT domain-
containing proteins have been studied and implicated in disorders, many of their 
particular substrates are still unknown and how these genes cause disorders are 
poorly understood. Interestingly, aprataxin, which causes ataxia with oculomotor 
apraxia 1 (AOA1), has been identified as a HIT family protein but is thought to 
form a new branch of HIT proteins because it binds DNA, in addition to RNA, and 
is implicated in DNA repair, in addition to its nucleotide hydrolase abilities82,86–88. 
The C19L1 domain is identified as “HIT-like” so it is unclear if CWF19L1 has 
hydrolase or transferase activity similar to the HIT-domain containing proteins.  
 
C19L1 also contains a metallophosphatase (MPP) domain in the N-terminus 
66,67,76. Metallophosphatases are a superfamily of enzymes that include a 
conserved domain that has an active site that bind two metal ions (manganese, 
iron, or zinc) and a cage of histidine, aspartate, and asparagine residues89,90. The 
MPP superfamily includes phosphoprotein phosphatases (PPPs), Mre11/SbcD-
like exonucleases, Dbr1-like RNA lariat debranching enzymes, YfcE-like 
phosphodiesterases, purple acid phosphatases (PAPs), YbbF-like UDP-2,3-
diacylglucosamine hydrolases, and acid sphingomyelinases (ASMases). These 
proteins are involved in a variety of cellular processes and encompass many 
different proteins. The MRE11 protein, which causes ataxia-telangiectasia-like 
disorder or progressive myoclonic ataxia, has an MPP domain and has been 
shown to be a part of the ATM DNA strand break repair pathway in ataxia91. 
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Additionally, DRN1, debranching enzyme-associated ribonuclease 1, is the S. 
cerevisiae ortholog of mug161 suggesting similarity to the debranching enzymes 
branch of the MPP superfamily. Further studies will be needed to determine the 
role of the C19L1 protein in brain development and function. 
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Figure 2.1. 13 genetic loci for ataxia identified by homozygosity 
mapping in Turkish consanguineous family 
 
Schematic of each chromosome is shown. Red boxes and cytogenetic 
map locations indicate approximate positions of positive regions of 
homozygosity larger than 500kB.  
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Figure 2.2. Exome sequencing data filtered by homozygosity 
identifies CWF19L1 as promising candidate gene 
 
Schematic demonstrates data filtration method used. Variants were 
narrowed by homozygosity mapping regions, variants that were contained 
in coding regions and that were predicted to be damaging (missense, 
nonsense, or splice site variants) to their encoded protein. 
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Figure 2.3. Genomic sequencing chromatogram validates exome 
sequence data 
 
Sequencing chromatogram demonstrates homozygous reference allele (G) 
in control individual. Sequencing of parental DNA demonstrates 
heterozygous (G/A) alleles indicated by black arrows. Affected individual 
shows homozygous variant allele (A) at the position indicated by filled 
arrowhead.  
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Figure 2.4. RT-PCR and sequencing demonstrates excision of exon 9 
 
(A) RT-PCR using primers in exons 8 and 10 show normal product bands 
in control individuals (lanes 2-4) but a ~100bp smaller product band in the 
affected individuals (lanes 5-6). No cDNA control shown in lane 7. Sanger 
sequencing verifies splicing out of exon 9. (B) Schematic of RT-PCR 
Sanger sequencing results.  
 
 
Controls Affecteds 
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Figure 2.5. No additional splicing aberrations shown by RT-PCR 
 
RT-PCR using primers in exon 9 (A), exons 7-11 (B), and exons 10-14 (C). 
Control samples in lanes 1-3. Affecteds in lanes 4-5. !!
Controls Affecteds 
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Figure 2.7. qRT-PCR shows decrease in CWF19L1 mRNA in affected 
individuals 
 
Primers were designed to exons 8-10 and normalized to GAPDH.  Affected 
individuals, shown by red bar, demonstrate ~6 fold decrease in CWF19L1 
mRNA in affected individuals 
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Figure 2.8. Immunoblot demonstrates loss of protein in LCLs of 
affected individuals 
 
A) Schematic of C19L1 protein isoforms. Red box indicates C19L1 
antibody epitope. (B) Western blot using C19L1 antiserum (Sigma) detects 
two C19L1 protein bands in control individuals. No protein bands are 
detected in patients. 30ug protein loaded. β-tubulin loading control. 
Predicted size of mutant truncated protein product is indicated by arrow. 
Aff Ctrl Aff Ctrl
affected
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Figure 2.9. Functional domains of CWF19 family members  
Schematic of CWF19 family of proteins in S. pombe, H. sapiens and D. 
rerio. Schematic showing C19L1 and C19L2 proteins demonstrating 
location of N-terminal metallophosphatase domain (MPP, blue box) and 
two C-terminal CwfJ domains (grey and orange box). The HIT-like domain 
is predicted to be buried within CwfJ domain 1 (grey box). !!
!
44!
Ta
bl
e 
2.
1.
 H
om
oz
yg
ou
s 
ex
om
e 
se
qu
en
ci
ng
 v
ar
ia
nt
s 
m
ap
pe
d 
in
 th
e 
ho
m
oz
yg
os
ity
 re
gi
on
s 
G
en
e 
C
hr
 
G
en
om
ic
 
po
si
tio
n 
N
uc
le
ot
id
e 
C
ha
ng
e 
Pr
ot
ei
n 
Pr
ot
ei
n 
C
ha
ng
e 
G
ER
P 
Sc
or
e 
Pr
es
en
t i
n 
EV
S 
C
D
C
73
 
1 
19
3,
21
8,
97
8 
A
->
T 
P
ar
af
ib
ro
m
in
 
M
is
se
ns
e 
0.
30
5 
N
 
A
TP
6V
1G
3 
1 
19
8,
49
8,
13
2 
C
->
A
 
A
TP
as
e,
 H
+ 
tra
ns
po
rti
ng
, l
ys
os
om
al
 
13
kD
a,
 V
1 
su
bu
ni
t G
3 
In
tro
ni
c 
-0
.7
33
 
N
 
C
2o
rf6
3 
2 
55
,4
03
,2
20
 
G
->
C
 
C
la
th
rin
 h
ea
vy
 c
ha
in
 li
nk
er
 d
om
ai
n 
co
nt
ai
ni
ng
 1
 
In
tro
ni
c 
0.
16
8 
N
 
C
C
D
C
88
A
 
2 
55
,5
82
,9
26
 
A
->
G
 
C
oi
le
d-
co
il 
do
m
ai
n 
co
nt
ai
ni
ng
 8
8A
 
In
tro
ni
c 
1.
75
 
N
 
X
P
O
1 
2 
61
,7
17
,7
13
 
A
->
G
 
E
xp
or
tin
 1
 
In
tro
ni
c 
-0
.2
68
 
N
 
C
1D
 
2 
68
,2
69
,9
74
 
G
->
T 
C
1D
 N
uc
le
ar
 R
ec
ep
to
r C
or
ep
re
ss
or
 
3'
 U
TR
 
1.
9 
N
 
C
LE
C
4F
 
2 
71
,0
43
,1
30
 
G
->
A
 
C
-ty
pe
 le
ct
in
 d
om
ai
n 
fa
m
ily
 4
, m
em
be
r F
 
S
yn
on
om
ou
s 
-6
.6
2 
N
 
LI
P
A
 
10
 
91
,1
22
,0
63
 
T-
>C
 
C
ho
le
st
er
yl
 E
st
er
as
e 
In
tro
ni
c 
-0
.6
91
 
N
 
R
P
P
30
 
10
 
92
,6
56
,1
45
 
T-
>C
 
R
na
se
 P
 P
ro
te
in
 P
30
 
S
yn
on
om
ou
s 
-1
0.
7 
Y
 
B
TA
F1
 
10
 
93
,7
46
,7
00
 
C
-.T
 
R
N
A
 P
ol
ym
er
as
e 
II,
 B
-T
FI
ID
 T
ra
ns
cr
ip
tio
n 
Fa
ct
or
 A
ss
oc
ia
te
d 
17
0k
D
 
In
tro
ni
c 
1.
44
 
N
 
S
O
R
B
S
1 
10
 
97
,1
43
,9
33
 
A
->
T 
S
or
bi
n 
an
d 
S
H
3 
D
om
ai
n 
C
on
ta
in
in
g 
1 
In
tro
ni
c 
-2
.9
1 
Y
 
C
O
X
15
 
10
 
10
1,
48
6,
38
4 
C
->
T 
C
yt
oc
hr
om
e 
C
 O
xi
da
se
 A
ss
em
bl
y 
H
om
ol
og
 1
5 
In
tro
ni
c 
0.
82
1 
N
 
C
W
F1
9L
1 
10
 
10
2,
00
5,
55
5 
C
->
T 
C
W
F1
9-
lik
e 
pr
ot
ei
n 
1 
S
pl
ic
e 
S
ite
 
5.
65
 
N
 
G
S
TO
1 
10
 
10
6,
02
5,
88
8 
C
->
A
 
G
lu
ta
th
io
ne
 S
 T
ra
ns
fe
ra
se
 o
m
eg
a 
1 
M
is
se
ns
e 
4.
2 
N
 
C
13
or
f2
3 
13
 
39
,5
85
,4
97
 
A
->
G
 
P
ro
lin
e 
an
d 
S
er
in
e 
R
ic
h 
1 
U
TR
-3
 
-5
.7
3 
N
 
D
C
LK
1 
13
 
36
,4
02
,0
11
 
G
->
A
 
D
ou
bl
ec
or
tin
-L
ik
e 
K
in
as
e 
1 
In
tro
ni
c 
-6
.2
6 
N
 
!
45!
! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !SOHL
H
2 
13
 
36
,7
44
,7
40
 
C
->
T 
S
pe
rm
at
og
en
es
is
 A
ss
oc
ia
te
d 
28
 
S
yn
on
om
ou
s 
2.
2 
Y
 
!
46!
Ta
bl
e 
2.
2.
 C
om
pl
et
e 
lis
t o
f s
ha
re
d 
ho
m
oz
yg
ou
s 
va
ria
nt
s 
th
at
 c
ha
ng
e 
en
co
de
d 
pr
ot
ei
n 
G
en
e 
C
hr
 
G
en
om
ic
 
po
si
tio
n 
N
uc
le
ot
id
e 
C
ha
ng
e 
P
ro
te
in
 
P
ro
te
in
 
C
ha
ng
e 
G
E
R
P
 
S
co
re
 
D
am
ag
in
g 
C
D
C
73
 
1 
19
3,
21
8,
97
8 
A
->
T 
P
ar
af
ib
ro
m
in
 
M
is
se
ns
e 
0.
30
5 
To
le
ra
te
d 
C
W
F1
9L
1 
10
 
10
2,
00
5,
55
5 
C
->
T 
C
W
F1
9-
lik
e 
pr
ot
ei
n 
1 
S
pl
ic
e 
S
ite
 
5.
65
 
- 
G
S
TO
1 
10
 
10
6,
02
5,
88
8 
C
->
A
 
G
lu
ta
th
io
ne
 S
- 
Tr
an
sf
er
as
e,
 O
m
eg
a 
1 
M
is
se
ns
e 
4.
2 
D
am
ag
in
g 
FC
G
R
2C
 
1 
16
1,
56
0,
94
3 
T-
>G
 
Fc
 F
ra
gm
en
t o
f I
gG
 
M
is
se
ns
e 
1.
52
 
P
ro
ba
bl
y 
O
R
2T
34
 
1 
24
8,
73
7,
25
9 
C
->
G
 
O
lfa
ct
or
y 
re
ce
pt
or
 2
T3
4 
M
is
se
ns
e 
1.
84
 
B
en
ig
n 
O
R
2T
34
 
1 
24
8,
80
1,
77
8 
A
->
T 
O
lfa
ct
or
y 
re
ce
pt
or
 2
T3
4 
M
is
se
ns
e 
1.
6 
P
ro
ba
bl
y 
R
A
B
6C
 
2 
13
0,
73
8,
16
3 
G
->
A
 
R
as
-r
el
at
ed
 p
ro
te
in
 
R
ab
-6
C
 
M
is
se
ns
e 
-1
.0
4 
To
le
ra
te
d 
U
G
T2
A
3 
4 
69
,7
95
,6
26
 
C
->
T 
U
D
P
-
G
lu
cu
ro
no
sy
ltr
an
sf
er
as
e 
2A
3 
M
is
se
ns
e 
2.
12
 
To
le
ra
te
d 
A
K
A
P
9 
7 
91
,6
46
,4
06
 
G
->
A
 
A
-K
in
as
e 
A
nc
ho
r 
P
ro
te
in
 9
 
M
is
se
ns
e 
-1
.0
3 
To
le
ra
te
d 
U
C
H
L3
 
13
 
76
,1
69
,0
58
 
G
->
A
 
U
bi
qu
iti
n 
Th
io
es
te
ra
se
 
M
is
se
ns
e 
-0
.7
12
 
To
le
ra
te
d 
P
O
TE
G
 
14
 
19
,5
62
,0
52
 
T-
>A
 
P
O
TE
-1
4 
M
is
se
ns
e 
0.
98
 
D
am
ag
in
g 
O
R
3A
3 
17
 
3,
32
4,
00
4 
C
->
T 
O
lfa
ct
or
y 
re
ce
pt
or
 3
A
3 
M
is
se
ns
e 
0.
17
8 
To
le
ra
te
d 
!
47!
! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !KRTAP
9-
8 
17
 
39
,3
94
,7
55
 
C
->
A
 
K
er
at
in
 A
ss
oc
ia
te
d 
P
ro
te
in
 9
-8
 
M
is
se
ns
e 
-4
.3
1 
To
le
ra
te
d 
K
IA
A
12
67
 
17
 
44
,1
44
,9
93
 
C
->
G
 
C
en
tro
m
er
e 
P
ro
te
in
 
M
is
se
ns
e 
3.
99
 
To
le
ra
te
d 
LR
R
C
37
A
2 
17
 
44
,6
26
,6
60
 
C
->
G
 
Le
uc
in
e-
R
ic
h 
R
ep
ea
t 
C
on
ta
in
in
g 
37
A
2 
M
is
se
ns
e 
-4
.4
7 
To
le
ra
te
d 
P
O
TE
C
 
18
 
14
,5
33
,1
05
 
G
->
C
 
P
O
TE
-1
8 
M
is
se
ns
e 
-2
.0
8 
To
le
ra
te
d 
!
48!
Ta
bl
e 
2.
3.
 L
is
tin
g 
of
 S
. p
om
be
 “
co
m
pl
ex
ed
 w
ith
 c
dc
5p
” 
(c
w
f) 
ge
ne
s 
an
d 
hu
m
an
 o
rt
ho
lo
gs
 
Ye
as
t 
G
en
e 
H
um
an
 
O
rt
ho
lo
g 
Pr
ot
ei
n 
D
el
et
io
n 
Ph
en
ot
yp
e 
Su
bc
el
lu
la
r 
Lo
ca
liz
at
io
n 
Fu
nc
tio
na
l 
D
om
ai
n(
s)
 
A
ss
oc
ia
te
d 
D
is
ea
se
/ 
A
ni
m
al
 
M
od
el
 
Fu
nc
tio
n 
pr
p5
 
cw
f1
 
P
LR
G
1 
Pl
ei
ot
ro
pi
c 
re
gu
la
to
r 1
 
In
vi
ab
le
 
N
uc
le
us
 
sp
ec
kl
e 
7 
W
D
40
 
re
pe
at
s 
E
m
br
yo
ni
c 
le
th
al
 m
ou
se
 
an
d 
ze
br
af
is
h 
In
te
ra
ct
s 
w
ith
 
cd
c5
L 
fo
r p
re
-
m
R
N
A
 s
pl
ic
in
g 
pr
p3
 
cw
f2
 
P
R
P
F3
 
U
4/
U
6 
sn
R
N
P 
90
 
kD
a 
pr
ot
ei
n 
In
vi
ab
le
 
N
uc
le
us
 
sp
ec
kl
e 
P
W
I 
do
m
ai
n 
 
A
D
 R
et
in
iti
s 
P
ig
m
en
to
sa
 
18
 
P
ar
t o
f t
he
 
U
4/
U
5/
U
6 
tri
-
sn
R
N
P
 c
om
pl
ex
, 
on
e 
of
 th
e 
bu
ild
in
g 
bl
oc
ks
 o
f t
he
 
sp
lic
eo
so
m
e 
sy
f1
 
cw
f3
 
X
A
B
2 
XP
A
-b
in
di
ng
 
pr
ot
ei
n 
2 
In
vi
ab
le
 
N
uc
le
us
 
14
 H
A
T 
do
m
ai
ns
, 
TP
R
 
do
m
ai
n 
N
on
e 
In
vo
lv
ed
 in
 
tra
ns
cr
ip
tio
n-
co
up
le
d 
re
pa
ir 
(T
C
R
), 
tra
ns
cr
ip
tio
n 
an
d 
pr
e-
m
R
N
A
 s
pl
ic
in
g 
sy
f3
 
cw
f4
 
C
R
N
K
L1
 
C
ro
ok
ed
 n
ec
k-
lik
e 
pr
ot
ei
n 
1 
In
vi
ab
le
 
N
uc
le
us
/ 
C
yt
op
la
sm
 
17
 H
A
T 
re
pe
at
s 
N
on
e 
In
vo
lv
ed
 in
 p
re
-
m
R
N
A
 s
pl
ic
in
g 
pr
oc
es
s 
!
49!
cw
f5
 
R
B
M
22
 
R
N
A
-b
in
di
ng
 m
ot
if 
pr
ot
ei
n 
22
 
In
vi
ab
le
 
N
uc
le
us
/ 
C
yt
op
la
sm
 
R
N
A
 
re
co
gn
iti
on
 
m
ot
if;
 
C
3H
1 
ty
pe
 
zi
nc
 fi
ng
er
 
M
ito
tic
 a
rr
es
t 
w
ith
 s
hR
N
A
 
kn
oc
kd
ow
n 
in
 c
el
ls
 
In
vo
lv
ed
 in
 th
e 
fir
st
 
st
ep
 o
f p
re
-m
R
N
A
 
sp
lic
in
g 
cw
f6
 
P
R
P
F8
 
22
0 
kD
a 
U
5 
sn
R
N
P-
sp
ec
ifi
c 
pr
ot
ei
n 
In
vi
ab
le
 
N
uc
le
us
 
S
pe
ck
le
 
M
P
N
 
(J
A
B
/M
ov
) 
do
m
ai
n;
 
R
R
M
 
do
m
ai
n 
A
D
 R
et
in
iti
s 
P
ig
m
en
to
sa
 
13
 
Fu
nc
tio
ns
 a
s 
a 
sc
af
fo
ld
 th
at
 
m
ed
ia
te
s 
th
e 
or
de
re
d 
as
se
m
bl
y 
of
 s
pl
ic
eo
so
m
al
 
pr
ot
ei
ns
 a
nd
 
sn
R
N
A
s 
sp
f2
7 
cw
f7
 
B
C
A
S
2 
B
re
as
t c
ar
ci
no
m
a-
am
pl
ifi
ed
 
se
qu
en
ce
 2
 
In
vi
ab
le
 
N
uc
le
us
- 
N
uc
le
ol
us
 
C
oi
le
d-
co
il 
N
on
e 
M
ay
 h
av
e 
a 
sc
af
fo
ld
in
g 
ro
le
 in
 
th
e 
sp
lic
eo
so
m
e 
as
se
m
bl
y 
as
 it
 
co
nt
ac
ts
 a
ll 
ot
he
r 
co
m
po
ne
nt
s 
of
 th
e 
co
re
 c
om
pl
ex
. 
pr
p1
9 
cw
f8
 
P
R
P
19
 
Pr
e-
m
R
N
A
-
pr
oc
es
si
ng
 fa
ct
or
 
19
 
In
vi
ab
le
 
N
uc
le
us
/ 
C
yt
op
la
sm
 
7W
D
40
 
re
pe
at
s,
 U
-
bo
x 
do
m
ai
n 
N
on
e 
D
N
A
 d
ou
bl
e-
st
ra
nd
 
br
ea
k 
(D
S
B
) 
re
pa
ir.
 E
ss
en
tia
l 
fo
r s
pl
ic
eo
so
m
e 
as
se
m
bl
y 
an
d 
st
ab
ili
ty
. M
ay
 h
av
e 
E
3 
ub
iq
ui
tin
 li
ga
se
 
ac
tiv
ity
. 
!
50!
sm
d2
 
cw
f9
 
sn
rp
d2
 
sn
R
N
P 
co
re
 
pr
ot
ei
n 
D
2 
In
vi
ab
le
 
N
uc
le
us
/ 
C
yt
op
la
sm
 
N
on
e 
N
on
e 
C
or
e 
co
m
po
ne
nt
 o
f 
th
e 
sp
lic
eo
so
m
al
 
U
1,
 U
2,
 U
4 
an
d 
U
5 
sm
al
l n
uc
le
ar
 
rib
on
uc
le
op
ro
te
in
s 
(s
nR
N
P
s)
, 
Th
er
eb
y,
 p
la
ys
 a
 
ro
le
 in
 th
e 
sp
lic
in
g 
of
 c
el
lu
la
r p
re
-
m
R
N
A
s.
 
cw
f1
0 
E
FT
U
D
2 
11
6 
kD
a 
U
5 
sm
al
l 
nu
cl
ea
r 
rib
on
uc
le
op
ro
te
in
 
co
m
po
ne
nt
 
In
vi
ab
le
 
N
uc
le
us
 
E
lo
ng
at
io
n 
fa
ct
or
 C
, P
-
lo
op
 
N
TP
as
e 
M
an
di
bu
lo
fa
ci
al
 d
ys
to
si
s 
w
ith
 
m
ic
ro
ce
ph
al
y 
(M
FD
M
) 
C
om
po
ne
nt
 o
f t
he
 
U
5 
sn
R
N
P
 a
nd
 th
e 
U
4/
U
6-
U
5 
tri
-
sn
R
N
P
 c
om
pl
ex
 
re
qu
ire
d 
fo
r p
re
-
m
R
N
A
 s
pl
ic
in
g.
 
B
in
ds
 G
TP
. 
cw
f1
1 
A
Q
R
 
In
tr
on
-b
in
di
ng
 
pr
ot
ei
n 
A
qu
ar
iu
s 
V
ia
bl
e 
cu
rv
ed
 
el
on
ga
te
d 
N
uc
le
us
 
N
on
e 
N
on
e 
In
tro
n-
bi
nd
in
g 
sp
lic
eo
so
m
al
 
pr
ot
ei
n 
re
qu
ire
d 
to
 
lin
k 
pr
e-
m
R
N
A
 
sp
lic
in
g 
an
d 
sn
oR
N
P
 (s
m
al
l 
nu
cl
eo
la
r 
rib
on
uc
le
op
ro
te
in
) 
bi
og
en
es
is
. 
is
y1
 
cw
f1
2 
IS
Y
1 
Pr
e-
m
R
N
A
-
sp
lic
in
g 
fa
ct
or
 
IS
Y1
 h
om
ol
og
 
V
ia
bl
e 
el
on
ga
te
d 
N
uc
le
us
 
N
on
e 
N
on
e 
re
gu
la
te
s 
th
e 
fid
el
ity
 o
f p
re
-
m
R
N
A
 s
pl
ic
in
g 
!
51!
pr
p4
5 
cw
f1
3 
S
N
W
1 
SN
W
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
1 
In
vi
ab
le
 
N
uc
le
us
 
S
N
W
, 
P
ro
lin
e 
ric
h 
do
m
ai
n 
N
on
e 
In
vo
lv
ed
 in
 
tra
ns
cr
ip
tio
na
l 
re
gu
la
tio
n.
 Is
 
re
qu
ire
d 
in
 th
e 
sp
ec
ifi
c 
sp
lic
in
g 
of
 
C
D
K
N
1A
 p
re
-
m
R
N
A
. 
cw
f1
4 
B
U
D
31
 
Pr
ot
ei
n 
B
U
D
31
(G
10
) 
ho
m
ol
og
 
V
ia
bl
e 
E
lo
ng
at
ed
 
N
uc
le
us
 
G
10
 
pr
ot
ei
n 
N
on
e 
C
om
po
ne
nt
 o
f t
he
 
S
F3
b 
su
bc
om
pl
ex
 
of
 th
e 
U
2 
sn
R
N
P
 
cw
f1
5 
C
W
C
15
 
Sp
lic
eo
so
m
e-
as
so
ci
at
ed
 p
ro
te
in
 
C
W
C
15
 h
om
ol
og
 
In
vi
ab
le
 
N
uc
le
us
 
C
oi
le
d 
co
il 
N
on
e 
C
om
po
ne
nt
 o
f t
he
 
P
R
P
19
-C
D
C
5L
 
co
m
pl
ex
 th
at
 fo
rm
s 
an
 in
te
gr
al
 p
ar
t o
f 
th
e 
sp
lic
eo
so
m
e 
an
d 
is
 re
qu
ire
d 
fo
r 
ac
tiv
at
in
g 
pr
e-
m
R
N
A
 s
pl
ic
in
g 
cw
f1
6 
C
C
D
C
94
  
C
oi
le
d-
co
il 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
94
 
V
ia
bl
e 
N
or
m
al
 
N
uc
le
us
 
C
oi
le
d 
co
il 
N
on
e 
m
ay
 b
e 
in
vo
lv
ed
 in
 
sp
lic
in
g 
sp
f3
8 
cw
f1
7 
S
N
R
P
40
 
U
5 
sm
al
l n
uc
le
ar
 
rib
on
uc
le
op
ro
te
in
 
40
 k
D
a 
pr
ot
ei
n 
V
ia
bl
e 
N
or
m
al
 
N
uc
le
us
 
7 
W
D
40
 
re
pe
at
s 
N
on
e 
C
om
po
ne
nt
 o
f t
he
 
U
5 
sm
al
l n
uc
le
ar
 
rib
on
uc
le
op
ro
te
in
 
(s
nR
N
P
) c
om
pl
ex
.  
!
52!
cw
f1
8 
C
C
D
C
12
 
C
oi
le
d-
co
il 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
12
 
V
ia
bl
e 
N
or
m
al
 
N
uc
le
us
/ 
C
yt
op
la
sm
 
C
oi
le
d 
co
il 
N
on
e 
m
R
N
A
 c
is
 s
pl
ic
in
g,
 
vi
a 
sp
lic
eo
so
m
e 
cw
f1
9 
C
W
F1
9L
2 
co
m
pl
ex
ed
 w
ith
 
C
dc
5 
pr
ot
ei
n 
C
w
f1
9 
V
ia
bl
e 
N
or
m
al
 
U
nk
no
w
n 
H
IT
-li
ke
, 
C
W
F_
J 
N
on
e 
m
R
N
A
 c
is
 s
pl
ic
in
g,
 
vi
a 
sp
lic
eo
so
m
e 
cw
f2
0 
P
R
C
C
 
Pr
ol
in
e-
ric
h 
pr
ot
ei
n 
PR
C
C
 
In
vi
ab
le
 
N
uc
le
us
 
P
R
C
C
 C
- 
te
rm
 
tra
ns
lo
ca
tio
n 
w
ith
 T
FE
3 
ex
pr
es
se
d 
in
 
pa
pi
lla
ry
 
re
na
l c
el
l 
ca
rc
in
om
a 
M
ay
 re
gu
la
te
 c
el
l 
cy
cl
e 
pr
og
re
ss
io
n 
th
ro
ug
h 
in
te
ra
ct
io
n 
w
ith
 M
A
D
2L
2.
 
cw
c2
1 
cw
f2
1 
S
R
R
M
2 
Se
rin
e/
ar
gi
ni
ne
 
re
pe
tit
iv
e 
m
at
rix
 
pr
ot
ei
n 
2 
V
ia
bl
e 
N
or
m
al
 
N
uc
le
us
 
S
pe
ck
le
 
C
oi
le
d 
co
il,
 
R
R
M
 
N
on
e 
In
vo
lv
ed
 in
 p
re
-
m
R
N
A
 s
pl
ic
in
g 
cw
f2
2 
C
W
C
22
 
Pr
e-
m
R
N
A
-
sp
lic
in
g 
fa
ct
or
 
C
W
C
22
 h
om
ol
og
 
In
vi
ab
le
 
N
uc
le
us
 
S
pe
ck
le
 
M
I d
om
ai
n,
 
M
IF
4G
 
do
m
ai
n 
N
on
e 
R
eq
ui
re
d 
fo
r p
re
-
m
R
N
A
 s
pl
ic
in
g 
an
d 
fo
r e
xo
n-
ju
nc
tio
n 
co
m
pl
ex
 (E
JC
) 
as
se
m
bl
y.
 R
ol
e 
in
 
no
ns
en
se
 
m
ed
ia
te
d 
de
ca
y 
!
53!
cw
f2
3 
D
N
A
JC
17
 
D
na
J 
ho
m
ol
og
 
su
bf
am
ily
 C
 
m
em
be
r 1
7 
In
vi
ab
le
 
N
uc
le
us
 
N
uc
le
uo
lu
s 
D
N
A
J 
do
m
ai
n,
 
R
R
M
 
do
m
ai
n 
N
on
e 
m
R
N
A
 c
is
 s
pl
ic
in
g,
 
vi
a 
sp
lic
eo
so
m
e 
cw
f2
4 
R
N
F1
13
A
 
R
IN
G
 fi
ng
er
 
pr
ot
ei
n 
11
3A
 
In
vi
ab
le
 
N
uc
le
us
 
R
IN
G
 ty
pe
 
zi
nc
 fi
ng
er
, 
C
3H
1 
ty
pe
 
Zi
nc
 F
in
ge
r 
N
on
e 
pr
ob
ab
ly
 in
vo
lv
ed
 
in
 m
ed
ia
tin
g 
pr
ot
ei
n-
pr
ot
ei
n 
in
te
ra
ct
io
ns
 
cw
f2
5 
C
W
C
25
 
Pr
e-
m
R
N
A
-
sp
lic
in
g 
fa
ct
or
 
C
W
C
25
 h
om
ol
og
 
In
vi
ab
le
 
C
yt
op
la
sm
 
C
oi
le
d 
co
il 
N
on
e 
m
R
N
A
 c
is
 s
pl
ic
in
g,
 
vi
a 
sp
lic
eo
so
m
e 
bu
d1
3 
cw
f2
6 
B
U
D
13
 
B
U
D
13
 h
om
ol
og
 
In
vi
ab
le
 
N
uc
le
us
/ 
C
yt
op
la
sm
 
C
oi
le
d 
co
il 
N
on
e 
m
R
N
A
 c
is
 s
pl
ic
in
g,
 
vi
a 
sp
lic
eo
so
m
e 
cy
p7
 
cw
f2
7 
C
W
C
27
 
Pe
pt
id
yl
-p
ro
ly
l 
ci
s-
tr
an
s 
is
om
er
as
e 
C
W
C
27
 
ho
m
ol
og
 
V
ia
bl
e 
N
or
m
al
 
U
nk
no
w
n 
P
P
Ia
se
 
cy
cl
op
hi
lli
n 
ty
pe
 
N
on
e 
pe
pt
id
yl
-p
ro
ly
l c
is
-
tra
ns
 is
om
er
as
e 
ac
tiv
ity
 
cw
f2
8 
G
P
K
O
W
 
G
 p
at
ch
 d
om
ai
n 
an
d 
K
O
W
 m
ot
ifs
-
co
nt
ai
ni
ng
 p
ro
te
in
 
In
vi
ab
le
 
N
uc
le
us
 
G
 P
at
ch
 
do
m
ai
n,
 
K
O
W
 
do
m
ai
n 
N
on
e 
Th
e 
en
co
de
d 
pr
ot
ei
n 
in
te
ra
ct
s 
di
re
ct
ly
 w
ith
 
pr
ot
ei
n 
ki
na
se
 A
 
an
d 
pr
ot
ei
n 
ki
na
se
 
X
 a
nd
 is
 a
ls
o 
fo
un
d 
as
so
ci
at
ed
 w
ith
 th
e 
!
54!
sp
lic
eo
so
m
e 
cw
f2
9 
R
B
M
X
2 
R
B
M
X2
 p
ro
te
in
 
V
ia
bl
e 
E
lo
ng
at
ed
 
N
uc
le
us
 
R
R
M
 
do
m
ai
n 
N
on
e 
sp
lic
eo
so
m
al
 
co
m
pl
ex
 a
ss
em
bl
y 
m
ug
16
1 
C
W
F1
9L
1 
C
W
F1
9-
lik
e 
pr
ot
ei
n 
1 
V
ia
bl
e 
N
or
m
al
 
N
uc
le
us
 
H
IT
-li
ke
, 
C
w
fJ
, M
P
P
 
N
on
e 
m
R
N
A
 c
is
 s
pl
ic
in
g,
 
vi
a 
sp
lic
eo
so
m
e 
!
! 55!
References 
 
1. Finsterer, J. (2009). Ataxias with autosomal, X-chromosomal or maternal 
inheritance. Can. J. Neurol. Sci. J. Can. Sci. Neurol. 36, 409–428. 
2. Sailer, A., and Houlden, H. (2012). Recent advances in the genetics of 
cerebellar ataxias. Curr. Neurol. Neurosci. Rep. 12, 227–236. 
3. Yapici, Z., and Eraksoy, M. (2005). Non-progressive congenital ataxia with 
cerebellar hypoplasia in three families. Acta Paediatr. Oslo Nor. 1992 94, 248–
253. 
4. Lander, E.S., and Botstein, D. (1987). Homozygosity mapping: a way to map 
human recessive traits with the DNA of inbred children. Science 236, 1567–1570. 
5. Alkuraya, F.S. (2013). The application of next-generation sequencing in the 
autozygosity mapping of human recessive diseases. Hum. Genet. 132, 1197–
1211. 
6. Foo, J.-N., Liu, J.-J., and Tan, E.-K. (2012). Whole-genome and whole-exome 
sequencing in neurological diseases. Nat. Rev. Neurol. 8, 508–517. 
7. Doi, H., Yoshida, K., Yasuda, T., Fukuda, M., Fukuda, Y., Morita, H., Ikeda, S., 
Kato, R., Tsurusaki, Y., Miyake, N., et al. (2011). Exome sequencing reveals a 
homozygous SYT14 mutation in adult-onset, autosomal-recessive 
spinocerebellar ataxia with psychomotor retardation. Am. J. Hum. Genet. 89, 
320–327. 
8. Li, M., Pang, S.Y.Y., Song, Y., Kung, M.H.W., Ho, S.-L., and Sham, P.-C. 
(2013). Whole exome sequencing identifies a novel mutation in the 
transglutaminase 6 gene for spinocerebellar ataxia in a Chinese family. Clin. 
Genet. 83, 269–273. 
9. Lee, Y.-C., Durr, A., Majczenko, K., Huang, Y.-H., Liu, Y.-C., Lien, C.-C., Tsai, 
P.-C., Ichikawa, Y., Goto, J., Monin, M.-L., et al. (2012). Mutations in KCND3 
cause spinocerebellar ataxia type 22. Ann. Neurol. 72, 859–869. 
10. Németh, A.H., Kwasniewska, A.C., Lise, S., Parolin Schnekenberg, R., 
Becker, E.B.E., Bera, K.D., Shanks, M.E., Gregory, L., Buck, D., Zameel Cader, 
M., et al. (2013). Next generation sequencing for molecular diagnosis of 
neurological disorders using ataxias as a model. Brain J. Neurol. 136, 3106–
3118. 
11. Morino, H., Miyamoto, R., Ohnishi, S., Maruyama, H., and Kawakami, H. 
(2014). Exome sequencing reveals a novel TTC19 mutation in an autosomal 
recessive spinocerebellar ataxia patient. BMC Neurol. 14, 5. 
! 56!
12. Doyle, A. (1990). Establishment of Lymphoblastoid Cell Lines. In Animal Cell 
Culture, J. Walker, J. Pollard, and J. Walker, eds. (Humana Press), pp. 43–47. 
13. Wu, C., Orozco, C., Boyer, J., Leglise, M., Goodale, J., Batalov, S., Hodge, 
C.L., Haase, J., Janes, J., Huss, J.W., 3rd, et al. (2009). BioGPS: an extensible 
and customizable portal for querying and organizing gene annotation resources. 
Genome Biol. 10, R130. 
14. Wood, V., Harris, M.A., McDowall, M.D., Rutherford, K., Vaughan, B.W., 
Staines, D.M., Aslett, M., Lock, A., Bähler, J., Kersey, P.J., et al. (2012). 
PomBase: a comprehensive online resource for fission yeast. Nucleic Acids Res. 
40, D695–699. 
15. Magrane, M., and Consortium, U. (2011). UniProt Knowledgebase: a hub of 
integrated protein data. Database J. Biol. Databases Curation 2011, bar009. 
16. Frank-Raue, K., Haag, C., Schulze, E., Keuser, R., Raue, F., Dralle, H., and 
Lorenz, K. (2011). CDC73-related hereditary hyperparathyroidism: five new 
mutations and the clinical spectrum. Eur. J. Endocrinol. Eur. Fed. Endocr. Soc. 
165, 477–483. 
17. Kang, T.H., Guibinga, G.-H., Jinnah, H.A., and Friedmann, T. (2011). HPRT 
deficiency coordinately dysregulates canonical Wnt and presenilin-1 signaling: a 
neuro-developmental regulatory role for a housekeeping gene? PloS One 6, 
e16572. 
18. Chowdhury, U.K., Zakharyan, R.A., Hernandez, A., Avram, M.D., Kopplin, 
M.J., and Aposhian, H.V. (2006). Glutathione-S-transferase-omega [MMA(V) 
reductase] knockout mice: enzyme and arsenic species concentrations in tissues 
after arsenate administration. Toxicol. Appl. Pharmacol. 216, 446–457. 
19. Hsu, L.-I., Chen, W.-P., Yang, T.-Y., Chen, Y.-H., Lo, W.-C., Wang, Y.-H., 
Liao, Y.-T., Hsueh, Y.-M., Chiou, H.-Y., Wu, M.-M., et al. (2011). Genetic 
polymorphisms in glutathione S-transferase (GST) superfamily and risk of 
arsenic-induced urothelial carcinoma in residents of southwestern Taiwan. J. 
Biomed. Sci. 18, 51. 
20. Kim, K., Kim, S.-H., Kim, J., Kim, H., and Yim, J. (2012). Glutathione s-
transferase omega 1 activity is sufficient to suppress neurodegeneration in a 
Drosophila model of Parkinson disease. J. Biol. Chem. 287, 6628–6641. 
21. Farhan, S.M.K., Wang, J., Robinson, J.F., Lahiry, P., Siu, V.M., Prasad, C., 
Kronick, J.B., Ramsay, D.A., Rupar, C.A., and Hegele, R.A. (2014). Exome 
sequencing identifies NFS1 deficiency in a novel Fe-S cluster disease, infantile 
mitochondrial complex II/III deficiency. Mol. Genet. Genomic Med. 2, 73–80. 
22. Dor, T., Cinnamon, Y., Raymond, L., Shaag, A., Bouslam, N., Bouhouche, A., 
Gaussen, M., Meyer, V., Durr, A., Brice, A., et al. (2014). KIF1C mutations in two 
! 57!
families with hereditary spastic paraparesis and cerebellar dysfunction. J. Med. 
Genet. 51, 137–142. 
23. Miyamoto, R., Morino, H., Yoshizawa, A., Miyazaki, Y., Maruyama, H., 
Murakami, N., Fukada, K., Izumi, Y., Matsuura, S., Kaji, R., et al. (2014). Exome 
sequencing reveals a novel MRE11 mutation in a patient with progressive 
myoclonic ataxia. J. Neurol. Sci. 337, 219–223. 
24. NCBI Resource Coordinators (2014). Database resources of the National 
Center for Biotechnology Information. Nucleic Acids Res. 42, D7–17. 
25. Ohi, M.D., Link, A.J., Ren, L., Jennings, J.L., McDonald, W.H., and Gould, 
K.L. (2002). Proteomics analysis reveals stable multiprotein complexes in both 
fission and budding yeasts containing Myb-related Cdc5p/Cef1p, novel pre-
mRNA splicing factors, and snRNAs. Mol. Cell. Biol. 22, 2011–2024. 
26. Ren, L., McLean, J.R., Hazbun, T.R., Fields, S., Vander Kooi, C., Ohi, M.D., 
and Gould, K.L. (2011). Systematic two-hybrid and comparative proteomic 
analyses reveal novel yeast pre-mRNA splicing factors connected to Prp19. PloS 
One 6, e16719. 
27. Rappsilber, J., Ryder, U., Lamond, A.I., and Mann, M. (2002). Large-scale 
proteomic analysis of the human spliceosome. Genome Res. 12, 1231–1245. 
28. Löscher, M., Fortschegger, K., Ritter, G., Wostry, M., Voglauer, R., Schmid, 
J.A., Watters, S., Rivett, A.J., Ajuh, P., Lamond, A.I., et al. (2005). Interaction of 
U-box E3 ligase SNEV with PSMB4, the beta7 subunit of the 20 S proteasome. 
Biochem. J. 388, 593–603. 
29. Brenner, C. (2002). Hint, Fhit, and GalT: function, structure, evolution, and 
mechanism of three branches of the histidine triad superfamily of nucleotide 
hydrolases and transferases. Biochemistry (Mosc.) 41, 9003–9014. 
30. Martin, J., St-Pierre, M.V., and Dufour, J.-F. (2011). Hit proteins, 
mitochondria and cancer. Biochim. Biophys. Acta 1807, 626–632. 
31. Hassan, M.I., Naiyer, A., and Ahmad, F. (2010). Fragile histidine triad protein: 
structure, function, and its association with tumorogenesis. J. Cancer Res. Clin. 
Oncol. 136, 333–350. 
32. Zhao, H., Race, V., Matthijs, G., De Jonghe, P., Robberecht, W., Lambrechts, 
D., and Van Damme, P. (2013). Exome sequencing reveals HINT1 mutations as 
a cause of distal hereditary motor neuropathy. Eur. J. Hum. Genet. EJHG. 
33. Zimoń, M., Baets, J., Almeida-Souza, L., De Vriendt, E., Nikodinovic, J., 
Parman, Y., Battaloğlu, E., Matur, Z., Guergueltcheva, V., Tournev, I., et al. 
(2012). Loss-of-function mutations in HINT1 cause axonal neuropathy with 
neuromyotonia. Nat. Genet. 44, 1080–1083. 
! 58!
34. Hirano, M., Yamamoto, A., Mori, T., Lan, L., Iwamoto, T., Aoki, M., Shimada, 
K., Furiya, Y., Kariya, S., Asai, H., et al. (2007). DNA single-strand break repair is 
impaired in aprataxin-related ataxia. Ann. Neurol. 61, 162–174. 
35. Kijas, A.W., Harris, J.L., Harris, J.M., and Lavin, M.F. (2006). Aprataxin forms 
a discrete branch in the HIT (histidine triad) superfamily of proteins with both 
DNA/RNA binding and nucleotide hydrolase activities. J. Biol. Chem. 281, 
13939–13948. 
36. Moreira, M.C., Barbot, C., Tachi, N., Kozuka, N., Uchida, E., Gibson, T., 
Mendonça, P., Costa, M., Barros, J., Yanagisawa, T., et al. (2001). The gene 
mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein 
aprataxin. Nat. Genet. 29, 189–193. 
37. Marchler-Bauer, A., Zheng, C., Chitsaz, F., Derbyshire, M.K., Geer, L.Y., 
Geer, R.C., Gonzales, N.R., Gwadz, M., Hurwitz, D.I., Lanczycki, C.J., et al. 
(2013). CDD: conserved domains and protein three-dimensional structure. 
Nucleic Acids Res. 41, D348–352. 
38. Marchler-Bauer, A., Panchenko, A.R., Shoemaker, B.A., Thiessen, P.A., 
Geer, L.Y., and Bryant, S.H. (2002). CDD: a database of conserved domain 
alignments with links to domain three-dimensional structure. Nucleic Acids Res. 
30, 281–283. 
39. Regal, J.A., Festerling, T.A., Buis, J.M., and Ferguson, D.O. (2013). Disease-
associated MRE11 mutants impact ATM/ATR DNA damage signaling by distinct 
mechanisms. Hum. Mol. Genet. 22, 5146–5159. 
 
 
! 59!
Chapter III. 
 
Zebrafish animal model demonstrates decreased protein levels, and 
abnormal behavior and development 
 
 
Introduction 
A novel splice mutation in CWF19L1 was found in affected Turkish siblings with 
congenital ataxia. The siblings also suffer from severe mental retardation and 
cerebellar hypoplasia (described in Chapter II)92. Exome sequencing in 
combination with homozygosity mapping identified a splice site mutation in the 
CWF19L1 gene. RT-PCR and immunoblot demonstrated decreased mRNA level 
and loss of C19L1 protein in patient-specific LCLs suggesting loss of the protein 
causes the ataxia. These results clearly demonstrate absence of the protein in a 
linked and homozygous region. However, private null mutations exist in about 
20% of humans93, and a function of CWF19L1 in ataxia is not immediately 
apparent, so we could not exclude the possibility that this could be a rare Turkish 
variant without pathological implications. One strategy to determine the function 
of a gene is to decrease or abolish expression of the gene to determine the 
effects of reduction or loss of the gene product. 
 
One method to accomplish this is to utilize morpholino-mediated gene 
knockdown in zebrafish. Morpholinos, which are small antisense 
oligonucleotides, can inhibit zygotic transcripts and can target specific
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sequences, creating a simple and effective method for studying mutations94. 
Morpholinos can be ubiquitously introduced into the developing zebrafish by 
injection into 1-2 cell embryos, and they result in gene knockdown that lasts a 
minimum of 4-7 days. Rapid generation time, large offspring number (100-300 
per clutch), ex utero development, and easily quantifiable motor behaviors make 
zebrafish an advantageous animal model to investigate human neurological 
disorders39,42,95.  
 
Recently, zebrafish animal models have been utilized to test the effects of genes 
implicated in ataxia (cite some of the papers here).  Additionally, zebrafish 
models can be used to identify the roles of newly discovered genes in 
development and other cellular processes so that we truly understand the role of 
a gene in normal brain function and in the ataxia disorders96–100. FANS, a 
mutation prediction program,  predicts the CWF19L1 variant we have identified to 
eliminate a splice site and to be highly damaging101. Splicing mutations have 
been studied in zebrafish using morpholino-mediated knockdown, in a variety of 
disorders, including primary microcephaly100, collagen myopathy14,15, and 
ataxia96,97,102.  Many splice site morpholinos have been shown to cause a 
locomotor phenotype in zebrafish which can often be shown using multiple 
morpholinos to the same exon or rescued using the human RNA for the 
gene96,97,99. These manipulations establish a causal relationship between the 
splicing mutation and disease phenotypes in humans. 
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The zebrafish cwf19l1 gene has 14 exons and shares 67% coding DNA identity 
with the human CWF19L1 gene67,103,104. The cwf19l1 gene is expressed 
ubiquitously in zebrafish, with higher expression in blood and head104,105 but 
currently the function and effects of mutations in this gene are unknown. Here, 
we use morpholino-mediated knockdown of the zebrafish cwf19l1 gene in 
combination with touch-evoked escape response and immunostaining to 
determine if severe deficiency or loss of cwf19l1 affects behavior and 
development of the fish as a model of the human disorder. 
 
Materials and Methods 
Zebrafish experimentation  
Wild type (AB strain) adult zebrafish were maintained in accordance with IACUC 
approved standards. Adult fish were mated to generate embryos for all 
subsequent analyses.  
 
Morpholino experiments 
A morpholino was designed to the exon 9 splice acceptor and donor sites of the 
zebrafish cwf19l1 gene (Figure 3.2). All studies were done as a comparison 
between the cwf19l1 morpholino and a standardized control morpholino (Gene 
Tools, Inc, Philomath, OR). The sequence of the cwf19l1 exon 9 splice acceptor 
morpholino is TGC TGG TTC TTC CTG ATC AAA GAG A and the sequence of 
the cwf19l1 exon 9 splice donor morpholino is AGA GTG CAT GTG AAT GGA 
CTC ACG T. The standard control morpholino sequence is CCT CTT ACC TCA 
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GTT ACA ATT TAT A. Morpholinos were injected into 1-2 cell stage embryos. 
Increasing concentrations were injected and screened by RT-PCR to determine 
efficacy in terms of interrupting splicing. The minimal dose for effect was 0.15 
mM for the splice acceptor (I8E9) and 0.45 mM for the splice donor (E9I9) 
therefore these concentrations were used for all subsequent experimentation.!!!
In silico analysis 
All sequences were obtained from the NCBI database76: 
mRNA:   H. sapiens (CWF19L1): NM_018294.4,  
D. rerio (cwf19l1):NM_001044758.1 
C19L1 Protein:   H. sapiens (C19L1): NP_060764.3,  
D. rerio (c19l1): NP_001038223.1 
Multiple Alignment using Fast Fourier Transform (MAFFT)106 
(http://mafft.cbrc.jp/alignment/software/) website was used to align C19L1 
sequences of human and zebrafish. Sequences used for MAFFT program are 
listed above. 
 
RNA extraction 
RNA was extracted from a minimum of ten fish using TRIzol reagent (Life 
Technologies, Grand Island, NY) and Zymogen Directzol RNA MiniPrep kit 
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(Zymo Research Corp, Irvine, CA) according to the manufacturer’s instructions. 
RNA was subjected to DNase I treatment (Ambion, Grand Island, NY) and 
reverse transcribed using the Invitrogen (now Life Technologies, Grand island, 
NY) SuperScript II reverse transcription kit using Oligo dTs and random 
hexamers. RT-PCR included primers that spanned exons 6 to 10 (F: 5’- TCG 
CAG ATC TCG CTG ACA AGC-3’; R: 5’- GCA AGG CAG AAC CAA CAG GGT-
3’) and primers to GAPDH (F: 5’- GTG TAG GCG TGG ACT GTG GT-3’; R: 5’-
TGG GAG TCA ACC AGG ACA AAT A-3’) for assessment of RNA.  
 
Protein electrophoresis and immunoblotting 
Described in Chapter II with the following changes: a minimum of 20 fish were 
collected from each condition at 72hpf (ctrl, I8E9 morphant, E9I9 morphant) and 
lysate was prepared in SDS sample buffer (1M Tris-HCL, pH 6.8, Glycerol, β-
mercaptoethanol, 20% SDS, and H2O) containing HALT protease inhibitor 
mixture (Thermo Scientific). Equal amounts of protein (15 µg per lane) were 
electrophoresed on SDS-PAGE gels. For c19l1, we used primary antibody 
HPA036890 (Sigma, St. Louis, MO) at a dilution of 1:2000; the secondary 
antibody was HRP-conjugated antibody against rabbit IgG diluted 1:10,000 
(BioRad, Hercules, CA, Cat. No. 170-6515). Blots were stripped with Restore 
Western Blot Stripping Buffer (Thermo Scientific Cat No. 21059) and reprobed 
with primary antibody GAPDH (Abcam, Cambridge, MA) at a dilution of 1:5,000 
using the same secondary antibody and ECL Western Blotting Substrate 
(BioRad, Hercules, CA). 
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Touch-evoked escape response 
Escape response was measured in morphant  zebrafish at 72 hpf. It was elicited 
by touching embryo tails with an eyelash filament. Response was graded from 0 
to 3; 0= no response to repeated stimulation; 1= flickers of movement but no 
swimming; 2= abnormal swimming in response to touch; 3= normal escape 
response107,108. Time-lapse video microscopy was used to record results. Fish 
were scored by three blinded investigators and scores averaged. A minimum of 
50 embryos per condition was utilized for behavioral assays. All experiments 
were performed 2-3 times. 
 
Whole-mount immunostaining 
Zebrafish larvae were fixed at 25°C in 4% PFA in PBST (PBS, 0.1% Triton X-
100) for 3 h. The fixed larvae were washed with PBST, and incubated in acetone 
at − 20°C for 15 min. Larvae were washed once with PBST and twice with PBS-
DT (PBS, 1% BSA, 1% DMSO, 1% Triton X-100), and incubated in 5% goat 
serum (Life Technologies, Grand Island, NY), PBS-DT at room temperature for 
1 h. The samples were incubated with the primary antibody (Anti-zebrin II (1:200, 
hybridoma supernatant)109,110, anti-Pvalb7 (1:1000, mouse ascites), anti-Vglut1 
(1:1000, purified antibody)) solution at 4°C overnight. After four washes with 
PBST, the samples were incubated with secondary antibodies (1:1000 dilution, 
Alexa Fluor 488 goat anti-mouse or Alexa Fluor 555 goat anti-rabbit, Molecular 
Probes (Invitrogen, Grand Island, NY)) and stained with DAPI (Thermo Fisher, 
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Rockford, IL).  Fish were mounted in 1% agarose and viewed on an Olympus 
Fluoview FV1000 confocal microscope. Confocal images were obtained using a 
10X objective. Images were acquired with Olympus FV1000 software and 
analyzed using ImageJ. 
For each condition, two investigators, who were blind to the injection cocktail, 
scored 25 embryos from 3 different experiments. Statistical significance was 
calculated using a Chi-squared test. 
 
Results 
Morpholino-mediated knockdown of cwf19l1 produces abnormal motor 
behavior and cerebellar development in zebrafish 
To test the effect of the CWF19L1 splice site mutation in vivo, we used a 
morpholino knock-down strategy (Figure 3.1) to the homologous intron-exon 
junction in zebrafish. Zebrafish cwf19l1 has 14 exons, shares 65% protein 
identity with the human CWF19L1 gene (Figure 3.2)67,104 and has the same 
predicted intron-exon structure.  
 
We designed morpholinos to the exon 9 splice acceptor and donor site (cwf19l1 
MOs) to target excision of exon 9, as in the affected individuals (schematic 
Figure 3.1). MOs were injected into 1-2 cell stage embryos and RNA was 
extracted at 3 days post fertilization (dpf). RT-PCR, using primers to exon 6 and 
exon 10, revealed the expected band of approximately 450bp in fish injected with 
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a standard control morpholino. However, RT-PCR from morphant fish injected 
with the cwf19l1 MOs demonstrated knockdown of the RT-PCR product with 
increasing morpholino concentration (Figure 3.3). Additionally, western blots 
performed with a C19L1 antiserum (HPA036890) demonstrated knockdown and 
loss of the c19l1 protein with increasing MO concentration (Figure 3.4), indicating 
deficiency, and loss at higher doses, of c19l1 in morphant fish. 
 
The gross morphology of the cwf19l1 morphant fish was normal overall. Images 
of the fish show no significant differences in size or morphology (Figure 3.5) at 
0.15 mM I8E9 and 0.45 mM E9I9.  
 
Behavioral analysis of cwf19l1 morphant embryos (as compared to control 
morphants) revealed reduced swim speed and abnormal touch-evoked escape 
response, a stereotyped behavior that is prominent at 3 dpf (see Figure 3.6 and 
supplemental videos (available upon request).  In contrast to their control 
morphant counterparts, cwf19l1 morphant fish, when touched with the eyelash 
filament, moved slowly and made circular movements instead of rapid movement 
straight away from the stimulus. As this response was elicited with both cwf19l1 
morpholinos, this suggests knockdown of cwf19l1 causes the abnormal motor 
behavior in these fish. Because the E9I9 MO required a higher dose to show 
morpholino effect, touch-evoked escape response was only quantified for 
comparison of 0.15 mM I8E9 and 0.45 mM E9I9 morphant fish.  Doses above 0.5 
mM are associated with an increase in mortality rate in control MO injected fish 
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and potential off target effects of the individual morpholinos94,111, therefore doses 
above 0.5 mM were not used for the E9I9 morpholino.   
 
Because the affected individuals showed cerebellar hypoplasia, we tested 
whether knockdown of cwf19l1 in morphant fish altered cerebellar development.  
Immunostaining with the zebrin II monoclonal antibody, which labels aldolase C 
positive cells 109,110, demonstrated altered/diminished cerebellar staining in I8E9 
morphants that worsened with increasing MO concentration (Figure 3.7). This 
suggests a defect in cerebellar structure. These results corroborate our earlier 
observation that c19l1 protein deficiency is associated with a neurological 
movement disorder and with cerebellar abnormalities. 
 
Discussion 
While the function of the cwf19l1 gene is unknown, its conservation from yeast to 
humans indicates an evolutionary importance. One strategy to determine the 
functional importance of a gene in an organism is to decrease or abolish 
expression of the gene to determine the effects of reduction or loss of the gene 
product. Zebrafish have recently been used to successfully study mutations in 
ataxia genes 96–99,102,112. In our study, knockdown of cwf19l1 in fish caused 
abnormal motor behavior and alteration of cerebellar structure. These data 
provide in vivo validation of our whole-exome sequencing results, demonstrating 
that loss of cwf19l1 causes an abnormal motor phenotype.  
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Specificity of the knockdown of the cwf19l1 gene was demonstrated by 
reproducible phenotypes obtained by two different morpholinos to the same 
exon. While the splice donor morpholino (E9I9) is predicted to cause direct 
splicing out of exon 9, the splice acceptor morphoino (I8E9) is predicted to cause 
inclusion of intron 8. However, since intron 8 is not divisible by 3 (as 
described in chapter II), inclusion of intron 8 is still expected to lead to nonsense- 
mediated decay of the RNA transcript, which is demonstrated by knockdown on 
RT-PCR. The specificity of knockdown is further confirmed by western blotting 
with a commercial antiserum (HPA036890) to the C-terminal end of c19l1. 
Decreased detection of c19l1 in the morphant fish demonstrates specificity of this 
antiserum.  
 
Additionally, examination of brain, and specifically cerebellar development, 
revealed decreased staining with zebrin II antibody, suggesting that the 
knockdown of cwf19l1 affected cerebellar development in the fish. Many forms of 
ataxia in human patients have a cerebellar structural defect as one of the clinical 
findings. Recent studies of ataxia genes that, when mutated, lead to cerebellar 
abnormalities in humans, have found evidence of abnormal cerebellar 
development in the zebrafish animal model 97,98,102. These studies, in 
 addition to our data, suggest conservation of genes that play a functional role in 
the development of the cerebellum between fish and humans, even if the exact 
morphology and primary cellular function are different.  
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While zebrin II staining has been used to demonstrate cerebellar abnormlities in 
zebrafish models of ataxia, we cannot differentiate between specific knockdown 
of cells that express aldolase C and abnormal cerebellum development. As such, 
I immunostained 5dpf fish with anti-Pvalb7 and anti-Vglut1 antibodies obtained 
from the Masahiko group in Japan50. Pvalb7 specifically labels the Purkinje cell 
layer and Vglut1 specifically labels the granule cell layer50. Unfortunately, staining 
with these antibodies according to previous published protocol revealed non-
specific positive staining in all brain regions of control and morphant zebrafish. 
Future studies using the α1-T-GFP transgenic zebrafish of the Goldman lab 
group at the University of Michigan113,114, which labels all α-tubulin positive 
neurons  in the fish with GFP, could be performed to analyze general neuronal 
development, including cerebellar development, without requiring 
immunostaining. 
 
There are currently no therapies for ataxia, therefore determining new pathways 
or targets for therapy are important. Recently, mouse models for spinocerebellar 
ataxia 1 and Friedreich’s ataxia have led to potential drug targets and clinical 
trials 13,14. Zebrafish are currently being used in studies for treatment of 
neurological disorders including bipolar disorder115 and epilepsy116,117. Since 
development and behavior can be easily visualized and manipulated in zebrafish 
larvae they represent a promising model for studying the effects of loss of 
cwf19l1 and for high throughput screening of therapeutic compounds to treat this 
recessive ataxia. Therefore in the future, this zebrafish model may also be used 
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to understand the function of C19L1, analyze and confirm cell experiments and 
ultimately test potential therapies for this form of ataxia.  
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Figure 3.1. Morpholino-mediated knockdown design 
 
Splice targeting morpholinos were designed to the intron 8/exon 9 (I8E9) 
splice acceptor site and to the exon 9 /intron 9 (E9I9) splice donor site.   
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Figure 3.2. Sequence similarity between human and zebrafish C19L1 
 
Amino acid alignment of the coding region for human (H. sapiens) and 
zebrafish (D. rerio) C19L1. * (asterisk) indicates conserved amino acids, . 
(period) indicates conservation between groups of weakly similar 
properties, : (colon) indicates conservation between groups of strongly 
similar properties 
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Figure 3.3. RT-PCR shows knockdown of cwf19l1 mRNA in morphant 
zebrafish 
 
RT-PCR of zebrafish cwf19l1 exons 6-10 indicate a loss of cwf19l1 RNA in 
morphants (0.15 mM I8E9 and 0.3 mM I8E9; lanes 4-5) with increasing 
morpholino doses as opposed to normal product in uninjected and control 
MO injected zebrafish (lanes 2-3). Lane 1: no DNA control 
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GAPDH 
Figure 3.4. Western blot shows knockdown and loss of cwf19l1 with increasing 
MO dose in cwf19l1 morphant fish 
Western blot with antiserum that recognizes 3’ end of c19l1 protein demonstrates loss 
of protein in morphant fish with increasing MO dose. GAPDH loading control !
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Figure 3.5. Gross morphology shows normal development in 
morphant fish 
 
Size and shape of Ctrl, I8E9, and E9I9 morphant fish are comparable in 
size and morphology 
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Fig 3.6. Touch-evoked escape response shows abnormal motor 
behavior in morphant fish 
 
cwf19l1 morphants had abnormal motor behavior. Depicted is a graph of 
the touch-evoked escape response (see also Movies S1- S4) (n = 5 
independently injected clutches, and a minimum of 10 embryos were 
assessed per clutch). 
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Figure 3.7. Zebrin II staining shows abnormal staining in cwf19l1 
morphant fish 
 
Zebrin II staining in 5dpf (A) control MO fish, (B) 0.15 mM I8E9 MO fish 
and (C) 0.3 mM I8E9 MO fish demonstrating gradually diminished staining 
in cerebellum with increasing MO dose (D) quantification (n=20 fish per 
condition, ** p<0.01, *** p<0.001). !!
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Chapter IV. 
 
 
Tissue distribution and location of C19L1, the CWF19L1-
encoded protein – preliminary data 
 
 
Introduction 
We have demonstrated that the ataxia/retardation syndrome in a Turkish sibship 
is associated with a splice site mutation that leads to splicing defects and loss of 
the c19l1 protein encoded by the CWF19L1 gene (Chapter II). While our genetic 
and molecular sequencing data were consistent with this mutation causing the 
syndrome, there are some deleterious mutations in every personal genome so 
we acquired independent evidence to demonstrate that our mutation causes 
ataxia1,2. To link CWF19L1 better to the ataxic phenotype, we generated a 
zebrafish model. We showed that reducing the cwf19l1 mRNA and C19L1 protein 
in zebrafish causes abnormal motor behavior and cerebellar development 
(Chapter III). However, while these results convincingly link the loss of this 
protein to ataxia, our experiments have not given us any information on the 
function of this gene at the cellular level. Much of the current information on 
CWF19L1 is based on predictions in databases. BioGPS, a database of gene 
expression studies, suggests this protein is ubiquitously expressed (Figure 4.1)3. 
While these databases give us a starting point for functional implications of this 
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gene, many of these predictions are based on high throughput experiments that 
have not been verified. One step to begin to characterize function is to determine 
tissue distribution and location in the cell4–6. Here we set out to determine the 
subcellular localization and tissue-specific expression pattern of CWF19L1.  
 
Materials and Methods 
Commercial lysates reagents 
Commercial tissue lysates for liver, stomach, cerebellum (left and right), spleen, 
heart, whole brain, frontal lobe, kidney, skeletal muscle, and lung were obtained 
from ProSci Incorporated (Poway, CA). HeLa cell line cytoplasmic lysates were 
also obtained from ProSci Incorporated. HeLa cell line nuclear lysates were 
obtained from Santa Cruz Biotechnology (Dallas, TX) and Abcam (Cambridge, 
MA). Commercial normal tissue brain lysates blot (15mg protein/lane; Cat. No. 
1526) and normal tissue lysates blot (15mg protein/lane, Cat. No. 1521) were 
obtained from ProSci Incorporated (Poway, CA).  
Tissue lysate preparation 
 All protein extractions were performed on ice with pre-chilled reagents and 
materials. Mouse tissues (Cerebellum, brain without cerebellum, lungs, heart, 
liver, stomach, kidney, and spleen) were homogenized in a glass dounce 
homogenizer in 1-2 mL of homogenization buffer (50mM Tris, 500mM NaCl, 
1mM EDTA, 0.5% NP40, 1x Protease Inhibitor Cocktail (Thermo Scientific), 1x 
PMSF, 0.1% SDS or 2% SDS). Homogenization was performed for 1-2 minutes 
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(approximately 50 strokes). Homogenate was centrifuged at 4oC in a pre-cooled 
microcentrifuge at 15,000 x g for 10-15 minutes to clear large debris. 
Supernatant was used immediately or flash-frozen with liquid nitrogen and stored 
at -80oC. Protein concentrations were measured using a commercial Bradford 
Assay (Bio-Rad, Cat. No. 500-0006).  
Protein electrophoresis and immunoblotting 
Described in Chapter II, Materials and Methods  
Immunofluorescence 
HeLa cells and human motor neuron (MN1) cells were grown and maintained in 
complete growth medium (1:1 mixture of DMEM and F12 medium, with 10% 
FBS) in 5% CO2 at 37°C.  
Cells were fixed in 4% PFA diluted in 1x PBS at room temperature for 1 hour. 
Cells were washed with TBS + TX100 for 10 minutes at room temperature, and 
then blocked with TBST-S for 30 minutes at room temperature. Primary 
antibodies were diluted in TBST-S at the following dilutions: anti-c19l1 antiserum 
(HPA036890, Sigma, St. Louis, MO) at 1:250 and anti- b-tubulin at 1:500, and 
incubated overnight at 4°C. Cells were washed 5x for 5 minutes each in TBST. 
Secondary antibodies and DAPI were diluted in TBST-S at the following dilutions: 
Alexa Fluor 555 (goat anti-rabbit, Molecular Probes, Invitrogen, Grand Island, 
NY) at 1:1000 and Alexa Fluor 488 (goat anti-mouse, Molecular probes, Grand 
Island, NY) at 1:1000 and incubated for 1.5 hours at room temperature. Five final 
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washes were performed: 4 times with TBST, and once with TBS. Cells were 
visualized using a fluorescence microscope. 
Results 
Tissue specific distribution of C19L1 
Immunoblots using HPA036889 antiserum revealed detection of this protein in 
almost all brain tissues including cerebellum (left and right), occipital lobe, 
parietal lobe, spinal cord, temporal lobe, and thalamus (Figure 4.2). Interestingly, 
we did not detect this protein in the frontal lobe using brain lysates (Figure 4.2). 
Additionally, only 1 band was detected in brain tissues, though lymphoblastoid 
cell lines and tissue lysates had 2 bands (Figure 2.8 and Figure 4.3). 
Examination of a commercial tissue lysates blot also revealed high detection of 
C19L1 protein in the brain, colon, heart, and kidney (Figure 4.3).  
 
Subcellular localization of C19L1 
In order to explore the impact of loss of the protein at the cellular level, we sought 
to determine the localization of the protein at the cellular level. Immunostaining 
using the HPA036890 antiserum showed nuclear localization of this protein in 
HeLa cells and MN1 cells (a motor neuron cell line) (Figure 4.5). To validate this 
result, immunoblot was performed on commercial nuclear and cytoplasmic 
lysates using the HPA036889 antiserum. Immunoblot showed a single band in 
the HeLa nuclear extract and no bands in the cytoplasmic extract. Ponceau stain 
of this blot demonstrates equal protein loading as antibodies used for loading 
control cannot detect protein in both cellular compartments (Figure 4.6).  
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Discussion 
The function of the C19L1 protein is unknown. We have demonstrated loss of 
this protein in individuals affected with ataxia and demonstrated abnormal 
behavior and development in a fish model; however our experiments do not 
provide functional information about this gene. The first step toward gaining 
insight into the function of a gene is to characterize the protein in tissues and at 
the cellular level. Immunoblots showed protein expression in the brain, heart, 
kidney, and colon. We detected no protein in the frontal lobe, although we 
detected protein in all other regions of the brain. Immunoblot revealed only the 
canonical protein band in the brain, suggesting this is the isoform present in the 
brain, though we cannot exclude undetectable levels of the other predicted 
isoforms of C19L1, as lower amounts of protein were loaded on the commercial 
blot (15mg vs 30mg for LCLs, Chapter II). As commercial lysates can vary 
significantly, I attempted to perform immunoblotting using the Sigma HPA036889 
antiserum on mouse tissue lysates however, the results between experiments 
were inconsistent suggesting the antiserum is not effective for mouse tissue 
lysates (Figure 4.7). 
  
It is unclear why loss of the c19l1 protein causes only a neurological phenotype. 
Importantly, there are examples of proteins that are expressed in multiple tissues 
but where a gain or loss of function mutation causes a phenotype only in a 
subset of organs in which the gene is expressed. Mutations in the SMN1 gene 
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cause spinal muscular atrophy7 although the protein is ubiquitously expressed 
and mutations in the gene cause motor neuron loss and skeletal muscle atrophy 
specifically in motor neurons7–12. Differences in impact of genetic mutations in 
specific tissues can be due to increased sensitivity of particular organs to 
changes in protein expression or due to tissue-specific interacting proteins or 
regulators 7–10. Further assessment of the function of C19L1 in neuronal cells is 
necessary in order to understand the requirements of this protein in neuronal 
tissue when compared with non-neuronal tissues.  
 
My studies of subcellular localization through immunofluorescence demonstrated 
nuclear localization of CWF19L1 in HeLa and MN1 cells (Figure 4.5). 
Immunostaining cells using the HPA036889 antiserum, even at very low 
dilutions, gave no signal suggesting this antibody cannot detect wild type protein. 
Immunostaining with the HPA036890 antiserum gave positive signal in the 
nucleus, however this antiserum (HPA036890) gave a non-specific minor band 
on LCL lysate western blots (Figure 4.7), suggesting it could be binding a non-
specific protein in the cell lysates. As such, nuclear and cytoplasmic lysates were 
obtained to validate these results using the HPA036889 antiserum. Immunoblot 
of cell compartment specific lysates showed a single band in the HeLa nuclear 
lysates suggesting C19L1 is localized in the nucleus.  
 
Yeast two-hybrid studies suggest that C19L1 interacts with proteins that are 
located in different compartments of the cell, providing inconclusive evidence13,14. 
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Proteomics assay suggest it is involved with the spliceosome and therefore part 
of the nucleus14–16, while another study suggests it interacts with TOM1L1, which 
is involved in a variety of cellular processes, but is generally localized in the 
cytoplasm13,17. Altogether, these results suggest nuclear localization and tissue-
specific distribution of C19L1. 
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Figure 4.1. BioGPS indicates ubiquitous expression of CWF19L1  
BioGPS expression data indicate human CWF19L1 mRNA is expressed in 
all cell types. Dataset: GeneAtlas U133A, gcrma; probeset: 218787_x_at. 
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Figure 4.2. Expression of C19L1 in brain tissue 
Western blot using C19L1 antiserum (Sigma) on brain lysates blot detects 
C19L1 in most brain tissues tested (61 kDa). 15ug protein loaded. GAPDH 
loading control.  
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Figure 4.3. Distribution of C19L1 in tissue lysates  
Western blot using C19L1 antiserum (Sigma) on commercial tissue lysates 
blot detects C19L1 in specific tissue lysates. 15ug protein loaded. GAPDH 
loading control.  
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Figure 4.4. Immunofluorescence detects C19L1 in nucleus  
Immunofluorescence for C19L1 (green, left panels) and nuclear marker  
DAPI (blue, middle panels) in (A) HeLa and (B) MN1 cell lines. Right 
panels show C19L1 and DAPI panels merged to indicate regions of co-
localization (green-blue, right panels).  
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Figure 4.5. Immunoblot detects C19L1 in nucleus  
(A) Western blot using C19L1 antiserum on commercial nuclear and 
cytoplasmic lysates detects C19L1 in nuclear lysate. 25ug protein loaded. 
(B) Ponceau stain shows loaded protein.  
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Figure 4.6 Immunoblot detects non-specific band in LCLs  
 
Western blot using C19L1 antiserum (Sigma) on LCL lysates shows minor 
band (arrow) at 23 kDa in all individuals. Pt- affected, ctrl- control. 30ug 
protein loaded. GAPDH loading control.  
 
 
 
 
 
CTRL    PT     CTRL     PT     CTRL 
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Figure 4.7. Immunoblot reveals inconsistent results between mouse 
tissue lysates !
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Chapter V. 
Conclusions and Future Directions 
 
Recent scientific advances have greatly increased our ability to study brain 
function. The lowered cost of exome sequencing and the improvements in cell 
lines and animal models have led to the identification of many disease genes and 
methods to study their pathogenesis1–4.  Studies of rare disorders are not just 
important for the few families involved, but provide important new information 
about function and dysfunction of genes and associated proteins, especially 
when the gene/protein is novel and has not been studied. Discovery of these 
genes is necessary to begin to gain information on how these particular genes 
lead to disease1,3.   
 
In this dissertation, I have identified a mutation in CWF19L1, a novel ataxia gene, 
utilizing exome sequencing and homozygosity mapping. Sanger sequencing 
confirmed this mutation in affected individuals and determined that it was absent 
in American and Turkish controls, demonstrating that this
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is not a common Turkish-specific polymorphism. RT-PCR and western blotting 
demonstrated instability of the mRNA transcript and deficiency of the protein. 
These results suggest that deficiency of the C19L1 protein, encoded by 
CWF19L1, causes the ataxia syndrome in the affected individuals. We also 
describe development of a zebrafish animal model in which to analyze the effect 
of mutation in this gene. Morpholino-mediated knockdown in zebrafish 
demonstrated increasing deficiency of c19l1 protein in a dose-dependent 
manner. Behavioral analysis of this model revealed abnormal motor behavior by 
touch-evoked escape response in a dose-dependent manner. Examination of the 
cerebellum in these fish showed decreased zebrin II immunostaining, also in a 
dose-dependent manner. These results suggest deficiency in the c19l1 protein 
causes abnormality in zebrafish motor behavior and development. Finally, initial 
characterization of this protein in human cells and tissues demonstrated nuclear 
localization of C19L1 and tissue specific distribution in the brain, heart, colon, 
and kidney but not in liver, lung, pancreas or spleen.  
 
Identification of a novel ataxia gene can be useful in the future for developing a 
clinical test for ataxia cases with unexplained etiology. Since it has been 
estimated that 40% of ataxias are not currently associated with genetic 
mutations, CWF19L1 is another potential gene candidate. Since this mutation 
was identified in a consanguineous family from a remote region in Turkey, this 
information can also be used for genetic testing. 
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Additionally, identification of the CWF19L1 gene can be used to analyze its role 
in cerebellar development. The affected individuals showed non-progressive 
cerebellar hypoplasia, suggesting abnormal development of their cerebellum due 
to deficiency of this protein. Our results demonstrated that morpholino-mediated 
knockdown of c19l1 in fish caused decreased zebrin II staining in the cerebellum. 
Additional work in the zebrafish can be utilized to help explain the mechanism for 
abnormal cerebellar development with loss of this gene. Our results suggested 
decrease in zebrin II staining in the cwf19l1 morphant zebrafish, however we 
cannot differentiate between loss of cerebellar cells and loss of the zebrin II 
marker. Future studies should analyze cell loss. Performing immunostaining 
using other antibodies to particular cerebellum cell types can be used to 
determine if the entire organ is affected or if particular cerebellum populations are 
affected. Pvalb7 and Vglut 1 antibodies have been used in studies to 
demonstrate specific loss of Purkinje and/or granular cell populations in 
zebrafish5–7. Conditional knockdown methods can also be used to determine the 
contribution of particular cell populations to the phenotype. Recent studies have 
demonstrated conditional knockdown of retina genes in zebrafish using 
electroporation8. PhotoMorphs are another novel method for conditional 
knockdown using morpholinos. PhotoMorphs are morpholinos with a 
photocleavable linkage that delays the activation of the morpholino until later 
stages of development. These PhotoMorphs are activated by UV light giving 
researchers spatiotemporal control of the morpholinos9,10.  
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Additionally, zebrafish are advantageous as they can be used to perform high 
throughput drug screening for therapy.  Zebrafish are also effective models 
because of high conservation of many genes from human to fish and because of 
easily observable traits in early larvae, including behavior, ex utero development 
and transparency at early stages11. Recent studies have used these advantages 
to test therapies for epilepsy, bipolar disorder, and Dravet syndrome12–14.  
 
Although the zebrafish model validated the effects of the CWF19L1 mutation, it is 
a limited model. While zebrafish share vertebrate brain structure, it is clear that 
there are also differences. Mouse models might provide further information about 
cerebellar development as mice have greater conservation of brain regions, 
including cerebellum organization15,16. Mouse models would also allow 
researchers to explore the extent of the ataxic phenotypes through multiple 
behavioral tests, including rotarod, grip strength, and footprint pathway tests17,18. 
Mice are also useful for testing cognition, as there are reliable methods to 
examine memory and learning17,18.  
 
While our results are important in establishing CWF19L1 as a disease gene, this 
work still has not described the function of this gene. We began to characterize 
C19L1 by immunoblot and found that it is distributed in brain, heart, kidney, and 
colon. Immunostaining revealed it is localized in the nucleus of HeLa and MN1 
motor neuron cells. C19L1 is implicated in the spliceosome machinery 
suggesting it might function to process mRNAs. RNA-Seq is a promising tool that 
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can be used to analyze splicing globally in our affected individuals to determine 
the effect of loss of C19L1. This method is advantageous because it can be used 
to sequence all RNAs in our affected individuals for abnormalities in splicing and 
can survey transcript isoforms and quantitate expression levels19.  Furthermore, 
C19L1 has an MPP domain and a HIT-like domain that are found in other ataxia 
genes20–23. Further studies that analyze the interactors of cwf19 in the 
spliceosome and that determine the effects of loss of cwf19 protein family 
members will be necessary to determine the protein’s function at the cellular 
level. Additionally, studies that disrupt the functional domains will help to assess 
the importance of the functional domains contained within it. Deletion studies in 
yeast demonstrate that cwf19 and mug161 knockout yeast are viable, however, 
they do not reveal phenotypes of the viable yeast24,25. As there are easily 
detected phenotypes for multiple cellular processes in the yeast, yeast may be a 
good model organism to explore the function of cwf19 family proteins and their 
encoded domains26,27. 
 
It is unclear why this mutation causes only a neurological phenotype when our 
data suggest it is expressed in multiple tissues. This phenomenon is not 
uncommon as there are other gain of or loss of function mutations that cause 
specific phenotypes when they are expressed in multiple tissues or even 
ubiquitously. For example, overexpression of DIAPH3 causes hearing loss 
though the gene is ubiquitously expressed28. Additionally, mutations in the SMN1 
and HD genes specifically cause spinal muscular atrophy and Huntington’s 
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disease respectively, though the genes are also ubiquitously expressed29,30.  
Current studies suggest specific effects of disease mutations rely on the 
requirements of genes in particular cell types, for example, heterozygous 
mutations in the PRPF3 (cwf2) lead to Retinitis Pigmentosa because of 
increased elevated splicing activity in the retina31. Additionally, gain of function or 
loss of function of a protein may cause downstream effects in the regulation of 
other proteins that are specific to particular tissues32,33. Further studies that 
address the function of this protein and the requirement of this protein in normal 
brain development will be necessary to understand why this mutation causes a 
specific neurological phenotype. 
 
In this work, we identified a mutation in CWF19L1, a novel ataxia gene, and 
demonstrated that the mutation causes deficiency of the protein and abnormal 
behavior and development in a zebrafish model. These findings revealed a novel 
gene that can be studied in future work to elucidate the role of this gene in brain 
development and function.
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